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ABSTRACT
Opioid abuse has become a global epidemic and is now a huge public health concern here in the
US. Non-medicinal use of opioid prescription drugs is at the forefront of the epidemic and
considered the “gateway” drug to other illicit opioid use. As opioid prescribing has increased
over the last decade in the US, so has opioid-related deaths, surpassing car accidents and suicide
as the leading cause of injury-related deaths. Medication assisted treatment (MAT) is
fundamental in decreasing opioid abuse overdose and mortality. Therefore, the research study
aims to determine if counseling adherence, opioid abstinence, and retention in MATs are
influenced by personal characteristics, socio-economic factors, readiness to change, social
support, and integrated care. Guided by social cognitive theory, transtheoretical model, and
theory of reasoned action, the study will employ a retrospective cohort design utilizing opioid
dependent patients from a MAT Program in West Florida. Analysis of three cox regression
models indicated for personal factors: an increase in age was associated with patients being more
likely to adhere to counseling (p=.001) and retention (p=.034), full-time employment (p=.043)
was positively associated with opioid abstinence, whereas part-time employment (p=.037) was
positively associated with retention, having insurance (public: p=.000) was positively associated
with counseling adherence, opioid abstinence (public: p=.000, private: p=.035) and retention
(public: p=.000, private: p=.000). With regards to environmental influences, social support was
positively associated with opioid abstinence (p=.022) and integrated care was positively
associated with opioid abstinence (p=.027) and retention (p=.000). Examining these factors are
necessary to improve treatment adherence and expand MAT programs. Additionally, providing
funding is crucial for practitioners to continually create educational intervention strategies to
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engage patients in treatment, thereby reducing the opioid overdose epidemic. This study extends
the literature contributing to understanding personal factors and environmental influences in
MATs.
Key words: medication assisted treatment, opioid dependence, treatment outcomes, socioeconomic factors, readiness to change, social support, integrated care, prescription drugs
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CHAPTER ONE: INTRODUCTION
Within the last decade, opioid abuse has become a major public health concern. The
prescription drug abuse epidemic has caused a substantial burden on society, including disease
transmissions as a result of injection drug use [Human Immunodeficiency Virus (HIV) and
Hepatitis C (HCV)], work productivity loss, and crime (Franckowiak & Glick, 2015; BantaGreen, Maynard, Koepsell, Wells, & Donovan, 2009; Hubbard, Craddock & Anderson, 2003).
The Centers for Disease Control and Prevention (CDC) has compared the current opioid
epidemic in the US to the HIV epidemic of the late 1980s and early 1990s (CDC, 2016a; Park &
Bloch, 2016, para 5; American Society of Addiction Medicine, n.d.). Overdose deaths as a result
of opioid drugs have surpassed car accidents as the leading cause of injury-related deaths in the
US (Hwang, Turner, Kruszewski, Kolodny & Alexander, 2016; CDC, 2011, Paulozzi, 2012).
Background
An estimated 2.2 million people in the US abuse opioids, of which 1.8 million are opioid
dependent (Substance Abuse and Mental Health Services Administration [SAMHSA], 2015;
Rusch, 2016). Non-medicinal opioid prescription drugs are considered a “gateway drug” and
have been at the forefront of the opioid epidemic (National Institute on Drug Abuse [NIDA],
2014; Maxwell, 2015; Zullig, Divin, Weiler, Haddox & Pealer, 2015). The increase in opioid
prescribing is associated with a surge in opioid diversion (medical prescriptions diverted to
others for recreational, non-medicinal purposes), opioid abuse, and unintentional overdose deaths
(Alford, 2016; Zosel, Bartelson, Bailey, Lowenstein, & Dart, 2013; Dowell, Haegerich, & Chou,
2016; Hwang et al., 2016; Turk, Dansie, Wilson, Moskovitz & Kim, 2014; Kresina & Lubran,
2011; Rusch, 2016).
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The state of Florida in particular, was sluggish to enact opioid prescribing restriction
laws, which resulted in an upsurge in opioid prescribing. In 2010, 98 of the top 100 oxycodoneprescribing physicians practiced in the state of Florida (Tozzie, 2014). Hence there was a
combined effort to decrease the crisis. Within the next two years this declined due to the
Prescription Drug Monitoring Program (PDMP) legislation signed in 2009 with mandatory
reporting requirements stating in 2011, The Drug Enforcement Agency Initiatives (Operation
Oxy Ally and Operation Pill Nation), and the Pill Mill Law, whose restrictions closed the illegal
practices of “pill mills” (Kennedy-Hendricks et al., 2016; Florida Senate, 2011). The rates have
therefore increased of those who sought another drug (heroin for instance) or effective treatment
through medication assisted treatment (MAT) programs to deal with withdrawals (Connery,
2015; Matson, Hobson, Abdel-Rasoul, & Bonny, 2014; Banta-Green et al., 2009; Timko,
Schultz, Cucciare, Vittorio & Garrison-Diehn, 2016).
SAMHSA (2015) notes the increase in the proportions of patients admitted nationally to
drug rehabilitation programs for opioid dependence -four percent for heroin and six percent for
non-medicinal prescription increase- due to the epidemic. The US Department of Health and
Human Services (HHS) has therefore made MAT a priority. In 2015, HHS discussed its
intentions to address treatment needs of those suffering with opioid dependence, and in 2016 the
US President’s budget included funding specifically for the expansion of using medicationassisted treatment to facilitate treatment for a large proportion of the population with opioid
dependence (Rusch, 2016).
MAT is a critical component to decreasing opioid abuse overdose and mortality (Dennis
et al., 2015; Rusch, 2016; Stotts, Dodrill, & Kosten, 2009; Jones, Campopiano, Baldwin, &
McCance-Katz, 2015; Kresina & Lubran, 2011). MAT is a chronic treatment approach for opioid
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dependence similar to treatment of diseases such as diabetes and hypertension (HHS, 2011;
Stotts et al., 2009). The monitored medication helps addicted individuals achieve a normal state
of mind (reducing cravings and withdrawals) and allows individuals to be productive citizens
(HHS, 2011, p. 5; Jones et al., 2015). MAT is a combination of medication and counseling
tailored to each person’s treatment needs, therefore maintenance and stabilization is
individualized and differs for each patient (HHS, 2011; Stotts et al., 2009).
Purpose of the Study
With the increase in opioid dependent individuals fueled by the prescription drug abuse
crisis, individuals successfully progressing through treatment are a vital component in reducing
the epidemic. Therefore, the research study aims to determine if counseling adherence, opioid
abstinence, and retention in MATs are influenced by:
1. Personal characteristics – gender, race, age, relationship status
2. Factors which contribute beyond personal characteristics, specifically socio-economic
factors – education, employment, income, health insurance
3. Readiness to change
4. Having a support system – social support
5. Receiving integrated care
The study will integrate the social cognitive theory, transtheoretical model, and theory of
reasoned action in order to assess these factors.
Significance of the Study
Drug-overdose deaths in the US have almost tripled within the last two decades, with
opioid-related deaths accounting for 60.9% (Rudd, Seth, David & Scholl, 2016). Florida is one
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of 19 states, which saw a statistically significant increase in drug overdose deaths between 2014
and 2015 (CDC, 2016b). Figures 1 – 4, illustrate the changes in drug-related deaths (if the drug
was the cause of death and present in the body at time of death) involving several types of
opioids, cocaine, and heroin in Florida, as indicated by the Medical Examiners Report (Florida
Department of Law Enforcement [FDLE], 2016). Figure 1 shows there was an increase in deaths
of three opioids until 2010, at which time deaths decreased and remained at a lower level for a
few years, then increased within the last year. The decrease in deaths correspond with the
combined legislative and law enforcement efforts -enactment of the Florida Pill Mill Law, DEA
Initiatives (Operation Oxy Ally and Operation Pill Nation)-, and later implementation of the
PDMP. Fentanyl (shown in figure 2) and heroin (shown in figure 4) have rapidly increased in the
last two years while cocaine (figure 3) has fluctuated in prior years and is on the rise again.

Figure 1. Historical overview of hydrocodone, oxycodone, and methadone deaths. This figure
illustrates the changes in Florida deaths inclusive of if the drug was the cause of death or
present in the body at time of death (FDLE, 2016).
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Figure 2. Historical overview of fentanyl deaths. This figure illustrates the changes in Florida
fentanyl deaths inclusive of if the drug was the cause of death or present in the body at time of
death (FDLE, 2016).

Figure 3. Historical overview of cocaine deaths. This figure illustrates the changes in Florida
cocaine deaths inclusive of if the drug was the cause of death or present in the body at time of
death (FDLE, 2016).
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Figure 4. Historical overview of heroin deaths. This figure illustrates the changes in Florida
heroin deaths inclusive of if the drug was the cause of death or present in the body at time of
death (FDLE, 2016).

With the current opioid abuse climate, determining effective treatment modalities are
essential. MAT is a prevention strategy to decrease opioid overdose deaths if patients are
engaged in treatment. High relapse and lack of retention in treatment has plagued those with an
opioid dependence. Considering the increase over the years in opioid prescription drug abuse,
and the consequential effects created, it is important to understand the personal characteristics
and socio-economic factors related to retention in treatment as well as the effects of readiness to
change, support systems and integrated care on counseling adherence, abstaining from opioids,
and retention in treatment. The study contributes to extending the literature on MAT and has
implications to support educational, regulatory, clinical and multidisciplinary intervention
strategies to combat the epidemic. The study provides a better understanding of factors that are
associated with treatment outcomes.

6

Definition of Terms
Counseling adherence (CA): patients complying with the counseling sessions/visits agreed on
in the initial treatment plan
Medication-assisted treatment (MAT): addiction treatment with medication and counseling for
opioid dependent individuals.
Opioids: drugs that interact with opioid receptors on nerve cells in the brain and body (often
prescribed to treat pain).
Opioid abstinence (OA): abstaining from all opioids during treatment with the exception of the
medication – methadone, buprenorphine.
Opioid dependence: the effects of opioid misuse results in changes to the brain that causes
addiction, and dependency on the drug.
Prescription drug abuse: the intentional use of psychoactive medications without a physician’s
prescription or in a way not advised by the prescribing doctor.
Retention (R): the length of time patients are engaged in medication treatment after admission
Socio-economic factors: social and economic measure of an individual’s status in comparison to
others based on education, employment, income and health insurance
Social support: being a part of a supportive social network i.e. friends, relatives
Stages of Change: assesses individuals’ readiness to change towards a healthier behavior
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CHAPTER TWO: LITERATURE REVIEW
The literature review section illustrates the magnitude of the research problem and
provides a frame of reference on opioid dependence and medication-assisted treatment. Relevant
literature on prescription opioid drug abuse, opioid dependence, MAT, indicators of successful
treatment outcomes, and possible factors related to treatment outcomes - personal characteristics,
socio-economic factors, readiness to change, social support and integrated care- are discussed.
The chapter concludes with the theoretical approaches: social cognitive theory transtheoretical
model, and theory of reasoned action, guiding the study.
Opioid Prescription Drug Abuse
Substance use remains an urgent public health problem, due to its physical, mental, social
and financial ramifications. Over $600 billion is lost annually in the US as a consequence of
substance use due to health care, crime, and work loss productivity (National Drug Intelligence
Center, 2010; NIDA, 2011; Franckowiak & Glick, 2015). In particular, opioid prescription drug
abuse has become a significant public health concern over the last decade, because of its
association with medical complications requiring emergency department visits, increased risks of
overdose, and mortality (Nargiso, Ballard & Skeer, 2015; Compton & Volkow, 2006; NIDA,
2014; Drazdowski, 2016; Phillips, 2013). Opioid prescription use for the treatment of pain has
increased over the last two decades primarily due to the aggressive marketing of pain
management (Zee, 2009; Phillips, 2013). The CDC has noted that the steady increase in opioid
prescribing shows a parallel increase in opioid addiction and overdose deaths (2016b).
Prescription drugs are comprised of the same drug categories as illicit drugs, therefore
similar pharmacological factors associated with addiction and abuse also apply to prescription
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drugs (Compton & Volkow, 2006). For instance, oxycodone, oxycontin, and hydrocodone are
opioids, the same category as heroin; whereas amphetamines and methylphenidate are
stimulants, like methamphetamine and cocaine (Compton & Volkow, 2006; Jones, Fullwood &
Hawthorne, 2012).
The CDC (2016b) indicates that over the last 2 decades the increase in opioid
prescriptions alone has resulted in an opioid overdose epidemic with approximately 115 deaths
per day. Of the 20% of the US population 12 years and older abusing prescription medications,
opioids, are one of the most misused (SAMHSA, 2013a; Fleary, Heffer & McKyer, 2011;
Phillips, 2013). Nearly 2 million Americans aged 12 or older were either dependent on or abused
prescription opioids in 2014 (CDC, 2016b). Many patients are prescribed doses that increase the
probability of becoming addicted to opioids (Caccavale, 2016).
Opioid Dependence
Pharmacological dependence, impaired control, risky use and social impairment are the
categories from which the DSM-V (Diagnostic and Statistical Manual of Mental Disorders) uses
to define at least two of the eleven criteria for the presence of a substance use disorder (Rusch,
2016). Opioid dependence is defined as “a chronic brain-based disorder with a high potential for
relapse” (Timko et al., 2016, p. 22). The complexity of opioid dependence has caused a
significant strain on the health care system (increased health care utilization, increased blood
borne viruses – HIV, HCV), criminal justice system, and family life to name a few (Stotts et al.,
2009; Timko et al., 2016). Those exposed to opioids follow a general path. Whether drugs are
obtained through diversion (for recreational use) or a prescription, tolerance evolves leading to
misuse (Rusch, 2016). Swallowing non-medicinal prescription drugs advance to chewing, then
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crushing, snorting and/or intravenous drug use, to release the drug more rapidly as the
dependence develops (Rusch, 2016, p. 8; Kresina & Lubran, 2011). Vulnerability to opioid
dependence is behaviorally complex, encompassing environmental, psychological, and
biological influences (Kresina & Lubran, 2011, p. 4103).
Annual treatment admissions for patients addicted to opioids have almost doubled within
the last decade in the US; with opioids only second to alcohol as the primary reason for
admission to addiction treatment (Timko et al., 2016; SAMHSA, 2015; Banta-Green et al., 2009;
Franckowiak, & Glick, 2015; Jones et al., 2015). In some states, admissions have increased 10fold, which is parallel to the increase in prescription opioid abuse (Banta-Green et al., 2009).
Opioid treatment (MAT) in communities are often limited, as abstinence is still seen as the
preferred method in many sectors – public, justice and legal system, mental health following the
Alcoholic Anonymous (AA) 12-step program, which is inadequate for opioid dependent
individuals (Rusch, 2016). For the last few decades, treatment programs have shifted from
abstinence to harm-reduction treatment supporting pharmacotherapy for opioid dependents
(Smyth et al., 2005).
Medication Assisted Treatment (MAT)
MAT is “the use of pharmacotherapies in combination with counseling and behavior
therapies to provide a comprehensive therapeutic approach to the treatment of opioid abuse and
dependence” (Kresina, & Lubran, 2011, p. 4104). MAT previously referred to as methadone
maintenance treatment was developed to reduce drug cravings and withdrawal symptoms
(sweats, chills, joint pain, vomiting, and diarrhea) and ultimately prevent relapse for opioid
dependent individuals (Rusch, 2016; Darker, Ho, Kelly, Whiston, & Barry, 2016; Jones et al.,
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2015). Appendix A provides a table summary of prior MAT studies. MAT is recognized as an
effective treatment choice for opioid dependence (Saxon, Hser, Woody, & Ling, 2013; Vogel,
Dürsteler, Walter, Herdener, & Nordt, 2017; Wasserman, Stewart & Delucchi, 2001; Darker et
al., 2016; Franckowiak & Glick, 2015; Jones et al., 2015). However, only an approximate eight
percent of those suffering from opioid dependence receive MAT (Vogel et al., 2017). The World
Health Organization (WHO) (2009) has advocated for long-term strategy care (open-ended
treatment, a lifetime of treatment if necessary) of MAT for this population. The Food and Drug
Administration (FDA) has approved three medications – methadone, buprenorphine, and
naltrexone for the treatment of opioid dependence (Timko et al., 2016).
Methadone.
The effectiveness of methadone maintenance treatment has been well established for
heroin addiction for decades (Cushman, Trussell, Gollance, Newman & Bihari, 1976; Dole &
Nyswander, 1976; Dole & Joseph, 1978; Kresina & Lubran, 2011; Kreek, Borg & Ray, 2010;
Banta-Green et al., 2009; Saxon et al., 2013; Jones et al., 2015). Due to the opioid epidemic
fueled by prescription drugs, an increasing number of opioid dependents who used nonmedicinal prescription drugs or poly users are seeking MAT. Due to cost, methadone is usually
the most utilized medication. Methadone is a synthetic opioid shown to reduce morbidity and
mortality in opioid dependents (research studies usually reference heroin-use addicts) (HHS,
2011; Timko et al., 2016; Darker et al., 2016). Methadone was previously dispensed in
“methadone maintenance clinics,” however many clinics now also dispense buprenorphine, and
have recently started naltrexone. After ingesting orally, methadone absorbs rapidly with initial
effects experienced within 30 minutes (Saxon et al., 2013; Darker et al., 2016). The complexity
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of methadone metabolism is evident in the enzymes ability to exhibit individual variation based
on environmental factors and genetics (Saxon et al., 2013, p. S70; Darker et al., 2016). The
average dose rages from 80 – 100 mg, however some patients stabilize at a lower or higher dose
(Saxon et al., 2013). Methadone is a full µ-opioid receptor agonist, while buprenorphine is only a
partial agonist (Saxon et al., 2013; Timko et al., 2016, p. 23). Feeling normal, with cravings
under control, minor or no side effects and no withdrawals, are indicators that individuals have
reached their stabilization dose (HHS, 2011). Withdrawal symptoms include: nausea, vomiting,
excessive sweating, diarrhea, anxiety and sleep issues (HHS, 2011). Side effects from methadone
include: drowsiness, respiratory problems, and constipation (Darker et al., 2016). Methadone can
be initiated at the start of recovery, unlike buprenorphine (once withdrawal has started), and
naltrexone (7 – 10 days after withdrawal, to ensure no opioids in the patient’s system) (HHS,
2011).
Buprenorphine.
The FDA approved Buprenorphine in 2002 for the treatment of opioid dependence. It is
used both in opioid detoxification and maintenance treatment (Timko et al., 2016).
Buprenorphine is usually referred to by its drug name of suboxone or subutex (generic drug).
The route of administration is sublingual through tablet or film in three formulations (Timko et
al., 2016; Saxon et al., 2013). Two of the sublingual formulations (tablet and film) are combined
with naloxone to prevent medication misuse via injection (Saxon et al., 2013). Withdrawals and
physical dependence is less severe with buprenorphine as a partial agonist versus methadone
(full agonist) (Timko et al., 2016, p. 23). “It has a ceiling effect on µ-opioid receptor” which
does not increase effects after ingesting a dose, decreasing the possibility of an overdose and
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depression (Saxon et al., 2013, p. S70). One of the benefits of buprenorphine is the ability to
receive a prescription outside of a maintenance treatment program (the sample for this study will
only include patients in a maintenance treatment program). A disadvantage is the cost; therefore,
it is less available to those without adequate resources (Timko et al., 2016).
Naltrexone.
Naltrexone is the only non-opioid treatment. It blocks all effects of opioids and does not
produce euphoric effects (Timko et al., 2016; Kresina & Lubran, 2011; Pecoraro, Ma & Woody,
2012). Unlike methadone and buprenorphine which activates opioid receptors to negate cravings,
naltrexone binds and blocks the receptors (SAMHSA, 2016, para. 2). It can be administered in an
extended release form -via injection once per month, intramuscularly- or orally in tablet form
(Timko et al., 2016). Starting treatment requires initial withdrawal from opioid substances for a
minimum of seven to ten days of detoxification prior, otherwise extra strong withdrawal effects
will be experienced (Kresina & Lubran, 2011; Stotts et al., 2009; SAMHSA, 2012). Naltrexone
does not require a taper or cause withdrawal symptoms if someone is stable in recovery and
wants to stop the medication (which should include physician consultation) (SAMHSA, 2012).
Indicators of Successful Medication Assisted Treatment Outcomes
MAT has showed improved ability for opioid dependents to function as respectable
citizens. Similar to diabetic or hypertension patients receiving medications for their illnesses, this
form of treatment for opioid addicts works. Counseling adherence, opioid abstinence and
retention in treatment are behaviors that have indicated decreases in drug use and mortality,
while improving the quality of life (Timko et al., 2016; Kelly, O’Grady, Mitchell, Brown &
Schwartz, 2011; Saxon et al., 2013; Banta-Green et al., 2009).
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Counseling Adherence.
Counseling is a benefit to MAT (as opposed to receiving a prescription outside of
maintenance treatment –an option for buprenorphine treatment) that provides individuals the
opportunity to understand the disease and delve into the causes and consequences of their
addiction (HHS, 2011). Counseling provides optimism and encouragement to overcome the
addiction (HHS, 2011). Receiving on-site counseling was positively correlated to treatment
retention in a research study, which integrated buprenorphine maintenance therapy at a Federally
Qualified Health Center (FQHC) (Haddad, Zelenev & Altice, 2013). The study also indicated
opioid use decreased as retention increased (Haddad et al., 2013). Since counseling is a benefit to
MAT, adherence to counseling should be an indicator of successful treatment outcomes of MAT.
Opioid Abstinence.
Opioid abstinence is an indicator of successful MAT because continued opioid use in
conjunction with MAT can create devastating effects for individuals, increasing the possibility of
cardiovascular dysfunction, overdose, and mortality (Kelly et al., 2011). A comparison of heroin
and prescription drug use dependents in a primary care office-based setting, concluded
prescription opioid dependent patients were more likely to have negative urine screens (56.3%
vs. 39.8%) (Moore et al., 2007). Opioid abstinence, reflective of a decrease in drug use is usually
an indicator of longer engagement in treatment (Kelly et al., 2011; Franckowiak & Glick, 2015).
Retention.
Treating opioid dependence is similar to that of other chronic illnesses, yet it is often
regarded as a semi-acute disorder (Vogel et al., 2017). Long-term care strategy principles, which
are accepted for chronic illnesses -such as diabetes, and obesity- are still not widely accepted or
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practiced for opioid use treatment (Vogel et al., 2017; McLellan, Lewis, O'Brien, & Kleber,
2000). Engaging in treatment for an adequate time is crucial for treatment to be effective (NIDA,
2011; Franckowiak & Glick, 2015). Studies have indicated patients in treatment for over a year
are more likely to be productive citizens, and reduce high-risk behaviors (SAMHSA, 2013b;
Kelly et al., 2011; Hubbard et al., 2003; Zhang, Friedmann, & Gerstein, 2003).
Banta-Green et al. (2009) note although methadone maintenance treatment for heroin
addicts have been assessed, there are limited studies on retention in treatment for prescription
drug use. A comparison of retention of opioid (heroin and prescription drugs) dependents in
Washington’s maintenance treatment programs, found no statistically significant difference in
treatment retention (Banta-Green et al., 2009).
Retention in MAT is an important outcome variable, as it correlates with long-term
positive societal and treatment outcomes (Banta-Green, et al., 2009; Darker et al., 2016; Kelly et
al., 2011). Retention in treatment decreases criminal involvement, increases education and social
function, whereas treatment drop out may lead to relapse, and other high-risk behaviors (Darker
et al., 2016; Compton & Volkow, 2006). Darker et al. (2016) notes that a higher rate in mortality
occurs 30 days after drop-out, and a significant proportion of opioid dependents fail to stay in
treatment.
Possible Factors Associated with Treatment Outcomes
Since MAT is a tool to prevent overdoses, abnormal cardiovascular function, and
premature death, it is important to examine factors associated with successful treatment
outcomes.
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Personal Characteristics
The characteristics of opioid dependents have changed from addicts in the past (BantaGreen et al., 2009). In recent years, with the prescription drug misuse epidemic, the opioid
dependence population has shifted to younger individuals, and there has been an increase in
whites and females. Studies have asserted that personal characteristics are associated with
treatment outcomes. However, there are disagreements in regard to gender, race, and relationship
status in the literature, with age being the only exception in which there is agreement (Deck &
Carlson, 2005; Joe, Simpson & Broom, 1998; Banta-Green et al., 2009; Darker et al., 2016;
Kelly et al., 2011; Wasserman et al., 2001).
Some studies have indicated the female gender as a predictor of positive treatment
outcomes. In a survival analysis on retention in methadone treatment being female was a
predictor of staying in treatment at 90 days (Kelly et al., 2011). Gender was a significant
predictor in a retention study of methadone maintenance programs in Western states, where
males were less likely to stay in treatment (Deck & Carlson, 2005). Gender was also
significantly associated with opioid use during treatment in one study, with males less likely to
abstain from opioids (Wasserman et al., 2001). However, another study found that gender was
not one of the predictive demographic factors of treatment outcomes (Darker et al., 2016)
Studies have found African Americans were less likely to stay in treatment in comparison
to Whites and Latinos. African Americans were only half as likely to stay in treatment in the
Washington sample from the two-Western state study (Deck & Carlson, 2005, p. 52). African
Americans were 31% less likely to continue treatment in comparison to whites, with no
significant differences between other races (Banta-Green et al., 2009, p. 778). Wasserman et al.
(2001) also found African Americans significantly associated with being less likely to stay in
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treatment, and to continue opioid abstinence. However, Kelly et al. (2011) found no statistical
significance with race and treatment outcomes.
Research has indicated age is positively associated with retention in treatment (Deck &
Carlson, 2005; Darker et. al, 2016; Joe et al., 1998; Banta-Green et al., 2009; Wasserman et al.,
2001). Age was determined to be a significant predictor in a retention study of methadone
maintenance programs in Western states (Deck & Carlson, 2005). In a binary logistic regression,
age (being older) was significantly associated with retention (Darker et al., 2016). Banta-Green
et al. (2009) noted 27% higher odds with every 10-year increase as a predictor for treatment
retention.
Limited studies have measured the association of relationship status to treatment
outcomes. Being single appeared to be associated with not having breaks in treatment in the chi
square analysis for an Ireland study, however the logistic regression indicated the relationship
was not significant (Darker et al., 2016). Relationship status significantly differed in an analysis
of variance (ANOVA), which measured days of opioid abstinence, with widows having longer
days of abstinence (Cavaiola, Fulmer & Stout, 2015).
Socio-economic Factors
Socio-economic status (SES) is a significant element in relation to disease and treatment
(Galea & Vlahov, 2002). Socio-ecological studies have noted the association with SES and
poorer health outcomes – mortality, various health risks in drug users (Galea & Vlahov, 2002):
“The existence of a social gradient, in which rates of morbidity and mortality decrease directly
and proportionately with each increase in level of income or education (Galea & Vlahov, 2002,
p. S137). Similar to personal characteristics, SES factors in drug abuse has shifted, with the
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prescription drug misuse epidemic increasingly affecting the middle class (Banta-Green et al.,
2009; Moore et al., 2007).
Few studies have researched SES as predictors of MAT treatment outcomes. When
researching demographic and clinical factors as predictors in a study conducted in Ireland,
employment and higher education were not predictors associated with retention in treatment
(Darker et al., 2016). Income at entry and during treatment was not associated with treatment
outcomes (Rash, Andrade & Petry, 2013; Rash, Olmstead, & Petry, 2009). Payment for services
(self-pay, private or public insurance) is an access factor in health care systems. Patients with
stable Medicaid eligibility were more likely to continue treatment - two and a half (2.5) times
more likely in Oregon, and two-thirds more likely in Washington State (Deck & Carlson, 2005).
Banta-Green et al. (2009) analysis also showed patients with public assistance funding Medicaid, TANF (Temporary Assistance for Needy Families)- were strongly associated with
retention in treatment.
Readiness to Change.
Long-term behavioral changes require action and adjustments over time (Office of
Behavioral and Social Sciences Research, n.d.). Motivation for treatment is an important aspect
in treatment success (Harrell, Trenz, Scherer, Martins & Latimer, 2013). Opioid dependent
individuals seeking treatment are at different stages in their ability to adopt a healthier behavior.
Readiness to change is a construct within the transtheoretical model (TTM) (which will be
discussed below) and includes 6 levels: pre-contemplation, contemplation, preparation, action,
maintenance and termination (Prochaska & Velicer, 1997; Prochaska, Redding & Evers, 2002;
Office of Behavioral and Social Sciences Research, n.d.). In researching predictors to retention
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in treatment, at the 90-day interval a higher treatment readiness at admission was a predictor
(Kelly et al., 2011). Harrell et al. (2013) in a latent class analysis noted patients in the “postaction” phase were significantly more likely to abstain from opioids, whereas the precontemplation class was significantly more likely to be positive for marijuana. Utilizing the
URICA (the University of Rhode Island Change Assessment) to measure motivation in change,
the assessment indicated individuals in the “committed action” stage were significantly
associated with alcohol and cocaine abstinence (Pantalon, Nich, Frankforter & Caroll, 2002).
Conversely, another study indicated no significance in readiness to change, but motivated
patients had decreases in illicit drug use and crime (Nosyk et al., 2010).
Support Systems.
It is believed that social support plays an important role in health and recovery in general.
Social support has shown to assist in the progression of treatment and abstinence from alcohol
and drugs (Cavaiola et al., 2015; Franckowiak & Glick, 2015). However, disagreement exists in
the literature in regard to social support improving treatment adherence and opioid abstinence.
Cocaine abstinence was predicted when patients in opioid maintenance therapy had social
support, but not opioid abstinence in a hierarchical logistic regression analysis (Wasserman et al.,
2001; Cavaiola et al., 2015). In addition, neither drug showed effects for general support on
abstinence (Wasserman et al., 2001). Cavaiola et al. (2015) whose sample was mainly heroin and
poly users (54.7% and 39.8% respectively), hypothesis was supported indicating social support
was a predictor of longer periods of abstinence and readiness to change. Unlike in the past,
recent research has shown those suffering with a substance use disorder usually have contact
with a family member (Cavaiola et al., 2015). Social support may play a significant role in
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assisting opioid abusers achieve abstinence, depending on the type of support received
(Wasserman et al., 2001).
Integrated Care.
Integrated care models are emerging due to the “clinical promise” of better health
outcomes and the cost effectiveness they contribute to both the patient and provider (Farber et
al., 2012; Kelly et al., 2011). Cooker et al. asserts integration is “a spectrum of organizational
arrangements relating to the funding, administration, organization, service-delivery and clinical
scenarios designed to create connectivity, alignment and collaboration” (as cited in Topp et al.,
2013, p. 348). Substance use patients often lack the connectedness and treatment network to
combat their illnesses; and often experience a high prevalence of additional medical disorders or
shortages in basic care. Access to the availability of needed services has the potential to
influence treatment outcomes.
If not addressed as part of medical treatment, complications can arise, and can lead to
reduction in treatment compliance (Farber et al., 2012). Integration of treatment services
therefore allows for a more holistic care to the patient, encouraging prevention and continuum of
care, in addition to more flexibility for the provider (Stone & Katz, 1996; Kelly et al., 2011;
Franckowiak & Glick, 2015). A study on the impact of MAT on co-occurring patients indicated
patients in integrated cognitive behavioral therapy in comparison to standard care had lower odds
of positive opioid urine drug screens (Saunders, McGovern, Lambert-Harris, Meier, McLeman &
Xie, 2015). The Community Access to Specialized Treatment (CAST) Initiative noted patients
receiving integrated care were more compliant to counseling adherence (Neufeld et al., 2010).
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Summary of Possible Factors Associated with Treatment Outcomes.
Opioid dependence and treatment for the disease is complex. Few studies have examined
the role of support systems and integrated care, in addition to personal characteristics and socioeconomic status on treatment outcomes in MAT (Heiman & Artiga, 2015; Galea & Vlahov,
2002; Wasserman et al., 2001; Cavaiola et al. 2015). There are limited studies focusing on MAT
outcomes, which primarily focus on non-medicinal prescription drug abuse opioid dependence
(Timko et al., 2016). Additionally, prior studies included smaller sample sizes and variation in
treatment outcomes. A need therefore exists to extend the literature on MAT programs for opioid
dependence and fill a critical gap focusing on prescription drug abuse addicts. As the opioid
epidemic has reached significant levels, in order to reduce mortality, it is important to understand
factors that impact higher rates of retention and successful outcomes for a better quality of life.
Theoretical Framework
Social Cognitive Theory.
Initially developed in the 1960s as the social learning theory, social cognitive theory
(SCT) was developed in 1986 (Bandura, 1986). Social context within environmental, personal,
and behavioral interaction are key constructs of the social cognitive theory (Office of Behavioral
and Social Sciences Research, n.d.; Sharma, 2005). The distinct way in which individuals
acquire and retain behavior in addition to the emphasis on social and environmental influences
and key characteristics (Office of Behavioral and Social Sciences Research, n.d.; Sharma, 2005).
The triangular model of the theoretical framework demonstrates the continual interaction of the
three factors: personal, environmental and behavioral (Office of Behavioral and Social Sciences
Research, n.d.; Sharma, 2005).
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The primary constructs of SCT include: knowledge, self-efficacy, outcome expectations,
goals, perceived facilitators, and impediments. Two of the domains SCT emphasizes for
substance use behavioral change include: outcome expectancies and self-efficacy. The belief of
specific behaviors resulting in certain outcomes (Gullo, Matveeva, Feeney, Young, & Connor,
2017). Self-efficacy abstinence has received greater attention in relation to substance use
treatment, in the ability to refuse or abstain from a substance. “Self-efficacy is a fundamental
requirement for behavior change” (Sharma, 2005. p. 3). SCT recognizes exposures/beliefs play a
pivotal role in consumption, dependence, and treatment (Gullo et al., 2017, p. 74). “Unless
people believe that they can produce desired effects by their actions, they have little incentive to
act or to persevere in the face of difficulties” (Bandura, 1999, p. 214).
Transtheoretical Model.
The transtheoretical model (TTM) emerged from theories in behavior change and
psychotherapy (Prochaska et al., 2002). The core constructs of the model are stages of change,
decisional balance, self-efficacy, and processes of change (Prochaska et al., 2002). This study
incorporates the stages of change construct, which is commonly assessed in substance use
treatment (Prochaska et al., 2002; Nosyk et al., 2010; Pantalon et al., 2002; Harrell et al., 2013).
A temporal dimension is expressed in the stage construct, and change involves progress through
the stages (Prochaska et al., 2002). Stages of change includes six stages: pre-contemplation,
contemplation, preparation, action, maintenance, and termination.
In this model, individuals in the initial stage, pre-contemplation, have no intentions in
taking action or making changes within the next six months in the near future (Prochaska et al.,
2002). Contemplation stage includes those who intend to take action and make changes within
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the next six months (Prochaska et al., 2002). Individuals in this stage are more aware of the
advantages and disadvantages of their behaviors, and are often stuck in the difficult balance of
the benefits and barriers (Prochaska et al., 2002, p. 100). Those in the preparation stage intend to
take action within the next 30 days, usually have an action plan, and have made behavioral
modifications (Prochaska et al., 2002). In the action stage, individuals have made observable
behavior changes for less than six months, whereas individuals in the maintenance stage have
made behavior changes for more than six months (Prochaska et al., 2002). In the final stage,
patients have full self-efficacy and no matter their circumstance are confident in not returning to
unhealthy habits (Prochaska et al., 2002).
Theory of Reasoned Action.
To improve the understanding within a broader context, the theory of reasoned action is
integrated with social cognitive theory as the theoretical base of the study. The theory of
reasoned action predicts and discerns motivational influences on a behavior (Fishbein & Ajzen,
1975; Madden, Ellen & Ajzen, 1992; Johnston, White & Norman, 2004). Created by Fishbein
and Ajzen (1975), the theory was revised and extended as the theory of planned behavior to
include perceived behavioral control. Behavioral intentions are a function of salient knowledge
or beliefs about the probability that doing a particular behavior will lead to a distinct outcome
(Fishbein & Ajzen, 1975; Madden et al., 1992; Millstein, 1996; McGinty & Anderson, 2008;
Fleming et al., 2016; Johnston et al., 2004). Behavioral, and normative are the two initial
constructs identified in the reasoned action approach (Fishbein & Ajzen, 1975; Madden et al.,
1992; Millstein, 1996; Fleming et al., 2016; Roberto, Shafer & Marmo, 2014; Rich, Brandes,
Mullan & Hagger, 2015; Johnston et al., 2004).
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Behavioral beliefs are the intrinsic influence on an individual’s attitude in performing the
behavior, while the normative beliefs involve the subjective norms (Fishbein & Ajzen, 1975;
Madden et al., 1992; Kleinman, Millery, Scimeca & Polissar, 2002). External elements affect
intentions, but only to the extent of influencing either attitudes or subjective norms (Madden et
al., 1992; Millstein, 1996). Therefore, the third belief, control was added. Control beliefs can
guide or impede an individual from carrying out a behavior (Fishbein & Ajzen, 2010). Inclusive
of environmental and personal factors, which facilitate positive outcomes in MAT; theory of
reasoned action explains that an individual’s actions (i.e. counseling adherence, opioid
abstinence, and retention) are the result of attitudes/behavior (treatment readiness), subjective
norms (social support) and intentions towards that behavior (Fleming et al., 2016).
Applications of the Theoretical Approach in Studies.
The literature on social cognitive theory, transtheoretical model and the theory of
reasoned action focuses on personal factors, elements in the environment and motivational
influences that can shape the responses of opioid addicts in MAT. The empirical studies discuss
survival and adoptions to innovations and necessary changes in the environment, in addition to
attitudes, subjective norms, motivations and control resulting in specific behavior. Each of the
studies emphasize at least one of the three core elements in the environment, stages of change, or
behavioral constructs, which influence the response. Appendix B provides a table summary of
the theoretical approaches literature review summary. Limited studies have utilized each theory
as a theoretical framework to guide associations in MAT for opioid dependence. However, social
cognitive theory and transtheoretical model has been utilized in addiction treatment research for
cannabis, alcohol, nicotine, cocaine; and theory of reasoned action in addition to addiction
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treatment research studies, has also been used in chronic illness studies.
A socio-cognitive analysis of substance use hypothesized that self-efficacy (a domain of
social cognitive theory) plays a key role in affecting every phase of treatment (initiation,
recovery, relapse, long-term treatment) (Bandura, 1999). Having a greater belief in treatment
success allows one to benefit more from treatment, and develop self-regulatory skills to succeed
(Bandura, 1999). Environmental factors were noted as a motivator of relapse. Bandura (1999)
therefore stressed the importance of a collective efficacy approach instead of an individualized
approach in treating substance use.
SCT was utilized as the framework to assess treatment outcomes and self-efficacy in a
substance use study on cannabis dependence (Gullo et al., 2017). Emotional relief refusal selfefficacy was a predictor of improved treatment outcomes; as abstinence increased with treatment
sessions (1.20 times more likely) (Gullo et al., 2017). Self-efficacy is usually noted in relapse
prevention approaches, influenced by social, personal and interpersonal key factors (Fiorentine
& Hillhouse, 2011). Low controlled use of self-efficacy was a predictor of abstinence
acceptance, which was associated with abstaining from drugs (Fiorentine & Hillhouse, 2011).
The self-efficacy to change has also been associated with readiness to change. Utilizing
the transtheoretical model to guide the framework of readiness for counseling and motivation to
change with prescription-drug dependent patients, significant associations were seen in those
with a higher readiness to change (p= .001) (Schmidt, Bischof, Harting & Rumpf, 2009).
Majority of the patients (56%) were in pre-contemplation stage, with the others either in
contemplation or in preparation stages (Schmidt et al., 2009). Patients in each stage group did not
differ in their readiness for counseling (Schmidt et al., 2009). Examining readiness to change
guided by TTM asserts readiness to change is a predictor of retention in methadone maintenance
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treatment, and opioid abstinence (Kelly et al., 2011; Harrell et al., 2013). Pantalon et al. (2002)
also associated a higher motivation to change with drug use abstinence.
Prochaska and Velicer (1997) assert at-risk behaviors (opioid dependence) are usually in
the initial three stages at the start of treatment. The majority is in pre-contemplation (40%) and
contemplation stages (40%), followed by preparation (20%) (Prochaska & Velicer, 1997).
Critical assumptions include, behavior change is a process, at-risk populations are not prepared
for action, no one theory can account for the complex nature of behavior change, and chronic
behavior patterns usually result from a combination of social, biological, and self-control
(Prochaska & Velicer, 1997).
In researching predictors of long-term treatment for heroin and cocaine addicts entering
detoxification Kleinman et al. (2002) asserts that the theory of reasoned action (in comparison to
the other theoretical approaches constructs) was the most effective in predicting use of treatment
programs. In the hierarchical multiple regression analysis, homelessness was the only significant
predictor in the first stage, in addition to criminal justice involvement and fewer than 20 years
using in the second stage (Kleinman et al., 2002). Behavioral beliefs and self-efficacy predicted
treatment utilization on the third stage with the addition of four help-seeking variables
(Kleinman et al., 2002).
Rich et al. (2015) meta-analysis studied the variance of intention and behavioral
outcomes for chronic illnesses. Inclusion studies had to examine health behaviors and/or
treatment as recommended by a health care provider and explicitly comprised at least one
construct of the theory (Rich et al., 2015). In regard to the effects of the theory constructs on
adherence behaviors, the correlations were significant (p < .05) and had medium to large effect
sizes. Perceived behavioral control, attitudes and subjective norms were statistically significant
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predictors of intention and treatment adherence behavior (Rich et al., 2015). The theory
explained 33% of variance in intention and 9% in adherence behavior (Rich et al., 2015).
Roberto et al. (2014) confirmed the theory of reasoned action as a conceptual model for
explaining attitudes and intentions and linkage of social norms in predicting substance-abuse
treatment providers encouraging patients to use MAT as part of their treatment plan. Significant
and substantial relationships were seen in each (behavior and intentions, attitudes and intentions,
and norms and intentions.
Conceptual Framework
Social cognitive theory, transtheoretical model and the theory of reasoned action together
provide a framework to understand the influence of factors on MAT outcomes. Figure 5
illustrates the integrated elements and behavioral constructs for the theoretical framework
conceptualized for the study.
The conceptual framework as illustrated in Figure 5 incorporates the triangular model of
SCT’s interaction of three elements: personal factors, environmental influences, and behavior.
The framework integrates the transtheoretical model into personal factors and the theory of
reasoned action into the three elements. The study will focus on the personal factors and
behaviors (treatment outcomes) relationship, examining the interaction of personal influences
and actions; in addition to the association of environmental influences and behaviors, looking at
that interaction and how it affects individuals’ behaviors.
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Figure 5. Conceptual Framework. This figure depicts an interwoven theoretical framework from
social cognitive theory, transtheoretical model, and theory of reasoned action.

The personal factors element incorporates individual characteristics, and factors which
contribute beyond personal characteristics in particular, socio-economic status. Although
individual behaviors are often associated with a wide range of factors that influence engagement
or barriers to healthy behaviors and treatment, research has shown the conditions in the
environment also affects risks and quality of life outcomes (Office of Disease Prevention and
Health Promotion, 2017; Heiman & Artiga, 2015). Heiman and Artiga (2015) estimate that 60%
of premature death risk is associated with individual behavior (40%) and social and
environmental factors (20%). Social cognitive theory takes into account personal factors and
social influences on the environment (internal and external) in understanding individuals’
behavior.

28

Readiness to change is the final variable in the personal factors element, taking from the
stages of change construct in the transtheoretical model. This also incorporates the self-efficacy
construct of SCT, in one’s ability to succeed. It measures the stage of participants in their
readiness to receive treatment, and incorporates the attitudes element from the theory of reasoned
action.
The environmental influences encompass subjective norms (theory of reasoned action),
and the physical environment. Subjective norms are the perceived social pressures to carry out a
behavior (Azjen, 1991). Determining if having a support system or lack thereof during MAT
may influence the treatment outcome. Access to the availability of needed services in the
primary treatment location, is a physical environmental factor that also has the potential to
influence behavior.
Behavior is an element in both the social cognitive theory and theory of reasoned action.
The outcome expectancies domain is a function of influences, knowledge and beliefs. Gullo et
al., 2017 note SCT recognizes influences and exposures are crucial elements in dependence and
treatment. The behaviors measured for treatment outcomes as discussed prior include counseling
adherence, opioid abstinence, and retention in treatment.
In summary, the conceptual framework indicates that personal factors (which
incorporates personal characteristics, socio-economic factors, readiness to change) and
environmental influences (subjective norms and physical environment) can impact behavior
(treatment outcomes in MAT for opioid dependence). Utilizing the combined theoretical
approach provides a framework for an examination of factors influencing MAT treatment
outcomes.
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CHAPTER THREE: METHODOLOGY
This section details the methodology used in the research study. The research questions and
hypotheses are identified, the research design is explained, and a description of the population
sample and variables are given. The ethical considerations of the study are also included. The chapter
concludes with the data collection methods and analytical strategy used.

Research Questions & Hypotheses
The study aims to answer the following research questions derived from the literature and
theoretical frameworks:
Research Question 1: Are personal characteristics associated with treatment outcomes in MAT?
Hypothesis 1A: Gender – identification as male is negatively associated with treatment
outcomes.
H1ACA: Male gender is negatively associated with treatment counseling
adherence.
H1AOA: Male gender is negatively associated with abstinence from opioids.
H1AR: Male gender is negatively associated with retention in treatment
Hypothesis 1B: Race - identification as African American is negatively associated with
treatment outcomes.
H1BCA: Identification as African American is negatively associated with
treatment counseling adherence.
H1BOA: Identification as African American is negatively associated with
abstinence from opioids.
H1BR: Identification as African American is negatively associated with retention
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in treatment.
Hypothesis 1C: Age is positively associated with treatment outcomes.
H1CCA: Age is positively associated with treatment counseling adherence.
H1COA: Age is positively associated with abstinence from opioids.
H1CR: Age is positively associated with retention in treatment.
Hypothesis 1D: Single relationship status is positively associated with treatment
outcomes.
H1DCA: Single - relationship status is positively associated with treatment
counseling adherence.
H1DOA: Single - relationship status is positively associated with abstinence from
opioids.
H1DR: Single - relationship status is positively associated with retention in
treatment.
Research Question 2: Are personal factors beyond characteristics, specifically socio-economic
factors, associated with treatment outcomes in MAT patients?
Hypothesis 2A: Higher education is positively associated with successful treatment
outcomes in MAT patients.
H2ACA: Higher education is positively associated with treatment counseling
adherence.
H2AOA: Higher education is positively associated with abstinence from opioids.
H2AR: Higher education is positively associated with retention in treatment
Hypothesis 2B: Employment is positively associated with successful treatment outcomes
in MAT patients.

31

H2BCA: Employment is positively associated with treatment counseling
adherence.
H2BOA: Employment is positively associated with abstinence from opioids.
H2BR: Employment is positively associated with retention in treatment.
Hypothesis 2C: Having a higher income is positively associated with successful
treatment outcomes in MAT patients.
H2CCA: Higher income is positively associated with treatment counseling
adherence.
H2COA: Higher income is positively associated with abstinence from opioids.
H2CR: Higher income is positively associated with retention in treatment
Hypothesis 2D: Having health insurance is positively associated with successful
treatment outcomes in MAT patients.
H2DCA: Having health insurance is positively associated with treatment
counseling adherence.
H2DOA: Having health insurance is positively associated with abstinence from
opioids.
H2DR1: Having health insurance is positively associated with retention in
treatment.
H2DR2: Having public insurance (Medicaid) is positively associated with
retention in treatment.
Research Question 3: Is readiness to change associated with treatment outcomes in MAT
patients?
Hypothesis 3A: Readiness to change is positively associated with treatment outcomes in
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MAT patients.
H3ACA: Readiness to change is positively associated with treatment counseling
adherence.
H3AOA: Readiness to change is positively associated with abstinence from
opioids.
H3AR: Readiness to change is positively associated with retention in treatment.
Research Question 4: Is having a support system associated with treatment outcomes in MAT
patients?
Hypothesis 4A: Having social support during treatment is positively associated with
treatment outcomes in MAT patients.
H4ACA: Having social support is positively associated with treatment counseling
adherence.
H4AOA: Having social support is positively associated with abstinence from
opioids.
H4AR: Having social support is positively associated with retention in treatment.
Research Question 5: Is integrated care associated with treatment outcomes in MAT patients?
Hypothesis 5A: Patients receiving integrated care are associated with positive treatment
outcomes in MAT.
H5ACA: Receiving integrated care is positively associated with treatment
counseling adherence.
H5AOA: Receiving integrated care is positively associated with opioid abstinence.
H5AR: Receiving integrated care is positively associated with retention in
treatment.
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Research Design
A retrospective cohort research design was utilized in this study to examine the
associations of personal factors (personal characteristics, socio-economic factors, and readiness
to change) and environmental influences (support systems and integrated care) on treatment
outcomes in MAT. Cohort studies examine specific sub-populations (opioid dependent
individuals in MAT) over time (Babbie, 2014). Retrospective cohort studies are observational
research designs, which examine prior data and investigate associations (risk or protective
factors) to an outcome (Sedgwick, 2014). An advantage of this design is the assessment of the
temporal sequence of factors and outcomes (Sedgwick, 2014). A limitation of this design is the
observational nature of the study does not indicate causal pathways (Jeffers et al., 2015;
Sedgwick, 2014). Observational or correlational research attempts to examine a relationship
between two or more variables using statistical data but cannot assign causation (Babbie, 2014).
Population & Sample
The population was adults who sought treatment at an accredited not-for profit MAT
program in West Florida. The not-for-profit behavioral health agency provides comprehensive
community-based medical, substance use, mental health and HIV services reaching over 25,000
individuals annually through prevention and treatment -detoxification, residential, intensive
outpatient, outpatient, and medication-assisted treatment. The MAT program has doubled in
admissions due to the prescription drug epidemic. Purposive sampling was utilized, specifically
targeting individuals admitted to the MAT program during July 1, 2014 – June 30, 2016.
Inclusion criteria includes a single episode of care for patients admitted during the study period.
The final treatment episode was used for patients who re-entered treatment. With implementation
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of the electronic health record (EHR), secondary data were retrieved from various sources within
the EHR, as identified in the last column of Table 1, for patients enrolled in treatment during the
study period.
Setting.
The MAT program provides services for adults (18 and older) seeking treatment for
opioid dependence. Patients are self-referred, court-ordered, or referred from medical providers
including pain management clinics, hospitals, and behavioral health programs. The program
provides methadone, buprenorphine, or vivitrol medication treatment to control cravings and
prevent withdrawals, while managing other medical conditions (onsite mental health, HIV and
primary care services are available). Patients on vivitrol were not included in the study, as those
patients’ records were not retrievable through the EHR. Patients also receive individualized
counseling in addition to their medications.
The program adheres to federal and state requirements for opioid treatment programs and
is supervised by a licensed physician. A patient can only be admitted to treatment after a
physician has determined the patient is physiologically addicted to opioid drugs for over a year
(exceptions include penal, pregnant, and individuals with prior maintenance or detoxification
treatment) (Florida Administrative Code, 2006). At the initial visit, patients complete a substance
use and mental health assessment, which confirms an opioid dependence diagnosis using DSMV. Additionally, the ASAM (American Society of Addiction Medicine) placement criteria guides
admission to the program. Patients may not be appropriate for outpatient treatment and referred
to residential, intensive outpatient, or detoxification. The current study focuses on patients in
outpatient treatment.
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Strict protocols exist for starting patients on a low dosage, which the medical staff then
monitors, and adjusts if necessary to stabilize the patient. A urine drug screen (UDS) is collected
at the initial visit and randomly throughout treatment, which patients are required to adhere to by
calling the urine drug screen line daily. Patients agree during the initial treatment plan to meet
with an assigned counselor to discuss treatment goals and prevent relapse.
Ethics.
Prior to the start of the study, an approval was received from the University of Central
Florida’s Institutional Review Board (IRB) to conduct human research. A HIPAA (Health
Insurance Portability and Accountability Act) Waiver of Authorization required by 45 CFR
(Code of Federal Regulations) 164.508 for the use or disclosure of protected health information
(PHI) was also received, since PHI was required to match the UDS labs in a separate system, and
patients’ consent was not received. The initial IRB approval (SBE-17-13277) was received on
July 5, 2017, and the modification approval inclusive of the HIPAA Waiver of Authorization
(HRP-441) was received on July 27, 2017.
Risks to subjects were minimized by securing and protecting identifiable information.
Data were recoded for analysis and secured (password-protected) on the Agency’s server with
only the researcher having access. All identifiable information was deleted once the recode was
completed within the three-month time period specified in the IRB protocol. Data will only be
reported in aggregate form, and the study’s data set will be deleted after the required retention
period of 5 years. Additionally, a business associate agreement was signed with the Agency, in
accordance with federal regulations governing the Confidentiality of Substance Use Disorder
Patient Records, 42 CFR Part 2; 45 CFR Parts 142, 160, 162, and 164, and HIPAA.
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Study Variables/ Measures
Variables of interest were determined from previously working in the behavioral health
field, and other analyses in the literature. Table 1 defines the operationalization of each variable
in more detail. Independent variables are: personal characteristics (patient’s gender, race, age
relationship status), socio-economic factors (education, employment status, income, and health
insurance), readiness to change, support system (social support), and integrated care. Controls
include: type of primary opioid dependence, criminal history, whether patients were courtordered, and the medication prescribed. The outcome variables of interest include: counseling
adherence, opioid abstinence, and retention in treatment.
Dependent Variables.
Counseling Adherence: captures whether the patient adheres to the counseling
sessions/visits agreed on in the treatment plan. Counseling adherence is a continuous variable
measured in weeks for the survival analysis based on the last counseling session date from the
date of admission.
Opioid Abstinence: assessed by urine drug screen (UDS) results. A negative result will
indicate a negative screen from opioid substances with the exception of methadone or
buprenorphine. Opioid Abstinence is a continuous variable measured in days for the survival
analysis based on negative urine drug screens. If screens were positive at admission, patients
were given a window period depending on the substance used. For instance amphetamines can
still be detected in UDS up to 48 hours after use, whereas diazepam can be detected up to 30
days after (Moeller, Lee & Kissack, 2008).
Retention: measured by the length of time patients are engaged in medication treatment
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after admission. For those with multiple treatment episodes, the final treatment episode was used.
Retention is a continuous variable measured in days for the survival analysis based on
medication dosing.
Independent Variables.
Personal Characteristics. There were four variables within this category: gender, race,
age, and relationship status, reported by the patient at admission.
Gender: was measured by the category the patient identifies as: 1= male, 2=
female. Male gender was the reference variable for the gender category (females compared
against).
Race: was measured by the category the patient identifies as: 1= White, 2= Black
or African American (AA), 3= Other at admission. White was the reference variable.
Age: A continuous variable of the patient’s age, based on date of birth at time of
admission.
Relationship status: was measured as reported by the patient at admission in the
following categories: 1= single, 2= married, 3= other. Other is inclusive of patients who were
divorced, separated, or widowed. Being single was the reference variable for the relationship
status category.
Socio-economic Factors. There were four variables within this category: education,
employment, income and health insurance
Education: was coded by the highest education level completed at admission.
Categories include 1= less than high school diploma, 2= high school diploma/GED (General
Equivalency Diploma), 3= vocational training, 4= some college, 5= college degree inclusive of
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any college degree attained. The lowest level attained, less than a diploma (elementary, middle
or high school), was the reference variable.
Employment: was coded by patient’s employment status at admission. 1=
unemployed, 2= not in the workforce, 3= part-time, 4= full-time. Not in the workforce category
was comprised of students, home-makers, those retired, disabled, on a leave of absence, or not
authorized to work. Unemployment was the reference variable.
Income: A continuous variable of the patient’s income at admission.
Health insurance: was based on patient’s payment method for services rendered
whether they had insurance or assistance. Patients were coded as 1= none, 2= public, 3= private.
Public included Veterans and Medicaid patients, as well as those receiving assistance from
federal and state funds or grants. Self-pay patients, those with no insurance was the reference
category.
Readiness to Change. This was assessed using the URICA (University Rhode Island
Change Assessment Scale) by the intake counselor. The scoring of the URICA and categories
was inclusive of four phases. 1= pre-contemplation, 2= contemplation, 3= action, and 4=
maintenance. Pre-contemplation was the reference variable.
Social Support. This was measured by patient’s report on having a support system during
their initial assessment. The two categories were 1= no, 2= yes. Having no support was the
reference variable.
Integrated Care. Patients who received additional services (i.e. mental health, HIV)
integrated in to MAT during care was measured by 1= no, 2= yes. Having no integrated care was
the reference variable
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Controls.
There were four variables within this category: opioid dependence, criminal history, court
ordered, and medication.
Primary Drug Dependence. At admission, patients reported their primary drug of choice.
Categories included 1= prescription medications, 2= heroin, 3= cocaine/crack, 4=
methamphetamine, 5= other. Prescription medications are narcotics, tranquilizers, and
amphetamines. The reference variable was prescription drugs.
Criminal History. Criminal history is self-reported at admission, based on the patients’
recollection of prior criminal record. The two categories were 1= no criminal history, 2= yes for
patients with a history. No criminal history was used as the reference variable.
Court Ordered. The intake counselor verified the referral source and indicated if the
patient was court-ordered to treatment. Patients were coded as 1= no (not court ordered) versus
2= yes (court-ordered to treatment). Not court-ordered was the reference category.
Medication. Categorized by the prescribed medication the patient received on initial
admission to the clinic. The medication prescribed was coded as 1= Methadone, 2=
Buprenorphine. Methadone served as the reference category.
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Table 1
Operational Definitions of the Study Variables
Variables
Type
Definition
Counseling
Dependent
Length of time patient
adherence
adhered to counseling
sessions agreed upon in
the initial treatment
plan
Opioid
Dependent
Length of time patient
Abstinence
abstained from opioids
since in treatment
Retention
Dependent
Length of time patient
is receiving medication
Personal
Independent Gender the patient
Characteristics:
identifies as at
Gender
admission
Personal
Independent Race the patient
Characteristics:
identifies as at
Race
admission

Measure
Continuous
SA: weeks

Data Source
Treatment –
Weekly
Note

Continuous
SA: days

Drug Screen

Continuous
SA: days
Categorical (2):
1= male*, 2=
female
Categorical (3):
1= White*, 2=
Black/AA, 3=
Other
Continuous

Admission
& Discharge
Admission

Admission

Personal
Characteristics:
Age
Personal
Characteristics:
Relationship
Status
Socio-economic
factor:
Education

Independent

Age of the patient at
admission

Independent

Relationship status as
reported by the patient
at admission

Categorical (3):
1=single*, 2=
married, 3= other

Admission

Independent

Highest education level
completed by the
patient at admission

Admission

Socio-economic
factor:
Employment

Independent

Patient’s employment
status at admission

Socio-economic
factor:
Income

Independent

Patient’s income at
admission

Categorical (5):
1= < high school
diploma*, 2=
high school
diploma/ GED,
3= vocational, 4=
some college, 5=
college degree
Categorical (4):
1= unemployed*,
2= not in the
workforce, 3=
part-time, 4= fulltime
Continuous
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Admission

Admission

Admission

Variables
Type
Socio-economic Independent
factor:
Health Insurance
Readiness to
Independent
Change

Definition
Patients form of
payment for services

Social Support

Independent

Integrated Care

Independent

Primary Drug
Dependence

Control

Patient’s report of
support systems during
initial assessment
Patients who received
additional services
integrated into MAT
treatment – HIV, MH,
Medical
Drug dependence at
time of admission

Criminal History Control

Court Ordered

Control

Medication

Control

Patient’s stage of
change assessed at
admission

Criminal history
reported at time of
admission
Patient court-ordered to
treatment
Medication prescribed
after admission into the
program

Measure
Categorical (3):
1= None*, 2=
Public, 3= Private
Categorical (4):
1= precontemplation*,
2= contemplation,
3= action, 4=
maintenance
Categorical (2):
1= no*, 2=yes

Data Source
Insurance/
Payment

Categorical (2):
1= no*, 2=yes

Treatment
Plan

Categorical (5):
1= prescription
medication*, 2=
heroin, 3= crack/
cocaine, 4=
methamphetamin
e, 5= other
Categorical (2):
1= no*, 2=yes

Admission

Categorical (2):
1= no*, 2=yes
Categorical (2):
1= methadone*,
2= buprenorphine

Admission

Admission,

Admission,
PSA

Admission

Medical
Order

* Reference variable
Data Collection
Permission to gain access to secondary data from the MAT Programs in West Florida was
granted in December 2016 by the Chief Executive Officer pending IRB approval. The Chief
Executive Officer provided a letter of support to conduct the study (see Appendix C), and
requested that a confidentiality clause is included to protect substance use patients in adherence
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with HIPAA and 42 CFR Part 2 the Confidentiality of Alcohol and Drug Abuse Patient Records
when completing the IRB protocol. With the merging of data sets for the urine drug screens, in
addition to cleaning and verifying any data needed, it was important to ensure the confidentiality
of patients’ health information. After IRB approval was received, data were obtained from three
systems that comprise the electronic health record (EHR) on September 6, 2017. Comprehensive
questions in the admission, psychosocial assessment, treatment planning and discharge were
used for the study variables.
Data Analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS) Program.
Data were first cleaned and coded to detect and remove errors for ensuring appropriate statistical
analysis. The initial data set included 5979 cases. However, the majority were duplicates which
had to be removed. Since the data were received in September, the data set also included
admissions beyond the study period which also had to be removed. Additionally, only the last
treatment of care was used for patients with multiple admissions. Univariate descriptive statistics
(measures of central tendency, dispersion and distribution) and identification of missing data
were then analyzed. In terms of missing values, SPSS uses pairwise exclusion which excludes
cases when data are missing for the particular analysis.
Bivariate statistical tests -correlations and ANOVA- examined the relationships between
the dependent (counseling adherence, opioid abstinence, and retention) and independent
variables. The covariates were analyzed for multicollinearity to ensure predictor variables do not
impact the models. Multicollinearity is not a concern when the independent variables are not
highly correlated (r =.8 or above) or when the variance inflation factor (VIF) is under 4.0 or

43

tolerances are above 40. Since the variables being measured were time-dependent, the Kaplan
Meier Method was conducted to demonstrate the bivariate relationships, and cox regression
models for the multivariate analysis.
Survival Analysis.
Survival analysis studies illustrate the time it takes for an event of interest to occur
(Kleinbaum, & Klein, 2005; Fox & Weisberg, 2011; Despa, n.d.; Parmar & Machin, 1995;
Allison, 2014). In addition to the time variable, survival analysis also includes censoring. A
paramount feature which accounts for observations when the survival time is incomplete
(Allison, 2014; Despa, n.d.) Right censored depicts patients who do not experience the event
during the study (Allison, 2014; Kleinbaum & Klein, 2005; Despa, n.d.). This also accounts for
missing data. Random and non-informative censoring is required to avoid bias in a survival
analysis (Kleinbaum & Klein, 2005).
Utilizing the wrong model and violating assumptions can lead to false inferences about
the regression (Allison, 1999). Since survival times are usually positive, using linear regression
would not be the optimum choice (Allison, 2014; Despa, n.d.). Regression techniques such as
ordinary least squares (OLS) cannot adequately handle censored observations, which survival
analysis incorporates in estimating important model parameters (Allison, 2014; Kleinbaum &
Klein, 2005; Despa, n.d., p. 1).
Kaplan Meier Method.
The Kaplan Meier Method estimates and illustrates survival probabilities as a function of
time (Despa, n.d., p. 2; Kleinbaum & Klein, 2005). It provides descriptive and bivariate statistics
of the variables.
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Cox (Proportional Hazards) Regression.
The cox regression model is the most widely used model providing information on the
hazard function to predictors (Kleinbaum & Klein, 2005; Fox & Weisberg, 2011). The model
examines the relationship between survival (dependent variables – counseling adherence, opioid
abstinence, and retention in treatment up to 365 days/ 52 weeks) and predictors.
Survival function is denoted as the probability a patient “survives” longer than a specified
time, S(t) = P (T > t) (Kleinbaum & Klein, 2005). While the hazard function provides the
“instantaneous potential per unit time for the event to occur; given that the individual has
survived up to time “t” and is considered the conditional failure rate (Kleinbaum & Klein, 2005,
p. 10). One function can be derived knowing the other, although on opposing ends (Kleinbaum &
Klein, 2005). The hazard function centers on failing, whereas surviving is the focus of the
survivor function.
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡 | 𝑇 ≥ 𝑡)
∆𝑡→0
∆𝑡

ℎ(𝑡) = lim
Where:

T= survival time (dependent variables)
t= specified value of t (52 weeks – counseling adherence, 365 days – opioid abstinence and
retention)
The cox proportional-hazard equation:
ℎ𝑖 (𝑡) = ℎ𝑜(𝑡) exp(𝛽1 𝑋𝑖1 + 𝛽2 𝑋𝑖2 + … + 𝛽𝑘 𝑋𝑖𝑘 )
Where:
hi (t) = hazard rate at time t
h0 (t) = baseline hazard
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β1 – 15 = regression coefficients
X = predictor variables
X1 = Personal Characteristics – gender
X2 = Personal Characteristics – race
X3 = Personal Characteristics – age
X4 = Personal Characteristics – relationship status
X5 = Socio-economic Factors – education
X6 = Socio-economic Factors – employment
X7 = Socio-economic Factors – income
X8 = Socio-economic Factors – health insurance
X9 = Readiness to Change
X10 = Social Support
X11 = Integrated Care
X12 = Opioid Dependence
X13 = Criminal History
X14 = Court Ordered
X15 = Medication
Power Analysis.
A priori power analysis determines if the expected sample is large enough to support this
analysis achieving desired effect size. Determination of minimum sample size is needed to make
generalizations to the population. Power is the odds of observing an effect when it occurs
(Farrokhyar, Reddy, Poolman & Bhandari, 2013). A priori power equation includes sample size

46

(number of units in the study), effect size (salience of treatment relative to noise), number of
predictors, and alpha level (odds that observed results are due to chance). Power = f(sample size,
effect size, number of predictors, alpha). With an anticipated effect size of 0.15, power level of
.8, 41 predictors and a probability level of .05, the priori power analysis indicated a minimum
sample size of 216 is required to reach statistically significant results.
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CHAPTER FOUR: RESULTS
The results section provides a detailed description of the analyses completed. The chapter
begins with a depiction of the study sample, then continues with the bivariate and survival
analyses conducted. The chapter concludes with an interpretation of the hypotheses testing.
Descriptive Analysis
The sample consisted of 1151 adults receiving MAT during the study period from July 1,
2014 to June 30, 2016. As shown in Table 2, the sample was predominantly female (61.4%),
White (86.6%) and single (68.2%). The mean age at time of admission was 34.72 years (standard
deviation = 9.926) ranging from 18 to 76 years. Almost 30% of the participants’ highest level of
education was less than a high school diploma or GED, 39.9% received a high school diploma or
GED, 3.4% completed vocational training, 17.2% completed some college courses, and 9.8%
had a college degree. The majority of participants were unemployed (56.9%), therefore the mean
income at time of admission was $825.29 (standard deviation = 5131.61). The majority of the
sample had some form of insurance or coverage -public 55% and private 9.4%- while 35.6% of
patients had no insurance and were considered self-pay. For the final variable under personal
factors, readiness to change, 29.5% of patients were in the initial phase of pre-contemplation at
intake, 34.8% in contemplation, 24.2% in action, and 11.5% were in the maintenance stage. In
terms of variables under environmental factors, the majority of patients 87.1% had some form of
social support, and 37.8% had received integrated care.
The study included four control variables: primary drug dependence, criminal history,
being court-ordered to treatment, and medication prescribed. The majority of patients had a
primary drug addiction to non-medicinal prescription drugs (68.1%) or heroin (27.7%), had no
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criminal history (81.5%), were not court ordered to treatment (93.4%) and were prescribed
methadone (93%).
In addition to the mean and standard deviation, the median is also reported due to the
normal curve being skewed for the three dependent variables which were time-dependent.
Counseling adherence measured in weeks had a median of 38.43 weeks, and mean of 32.80
(standard deviation = 20.104). Opioid abstinence measured in days had a 77.21 median and mean
of 139.47 (standard deviation = 131.230). Retention was also measured in days had a 182.50
median, and mean of 202.91 (standard deviation = 136.520). Detailed characteristics of the
sample is illustrated in Table 2.
Table 2.
Sample Characteristics
N= 1151
Gender
Male
Female
Race
White
Black/AA
Other
Age
Relationship Status
Single
Married
Other
Education
< high school
High school
Vocational
Some college
College Degree
Employment
Unemployed
Not-in workforce
Part-time
Full-time

N

%

444
707

38.6
61.4

986
51
102

86.6
4.5
9.0

773
166
194

68.2
14.7
17.1

245
329
28
142
81

29.7
39.9
3.4
17.2
9.8

472
189
45
124

56.9
22.8
5.4
14.9
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Median

Mean

(SD)

33.00

34.72

9.926

N= 1151
Income
Insurance
None
Public
Private
Readiness to Change
Pre-contemplation
Contemplation
Action
Maintenance
Support System
No
Yes
Integrated Care
No
Yes
Drug Dependence
Prescriptions
Heroin
Crack/Cocaine
Methamphetamine
Other
Criminal History
No
Yes
Court. Ordered
No
Yes
Medication Prescribed
Methadone
Buprenorphine
Counseling Adherence
(weeks)
Opioid Abstinence
(days)
Retention
(days)

N

%

410
633
108

35.6
55.0
9.4

305
360
250
119

29.5
34.8
24.2
11.5

148
1003

12.9
87.1

716
435

62.2
37.8

616
251
10
6
22

68.1
27.7
1.1
0.7
2.4

710
161

81.5
18.5

845
60

93.4
6.6

1071
80

93.0
7.0
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Median
0.00

Mean
825.29

(SD)
5131.613

38.43

32.80

20.104

77.21

139.47

131.230

182.50

202.91

136.520

Bivariate Analysis
Comparisons between continuous variables were analyzed using the Pearson correlation
coefficient (r). For categorical variables, the means of the dependent variables were compared
between groups, using the Fischer’s test (F). For statistical significant differences between
groups of three or more, the post-hoc comparisons using the Tukey HSD test was analyzed.
Correlation.
As depicted in Tables 3, 4 and 5, there were no significant correlations between the
continuous independent variables (age and income) with the dependent variables.

Table 3
Correlations between counseling adherence and continuous independent variables
Variable
N
R
Age
623
.058
Income
445
-.012

P-value
.145
.802

Table 4
Correlations between opioid abstinence and continuous independent variables
Variable
N
R
Age
1118
.027
Income
778
.064

P-value
.370
.076

Table 5
Correlations between retention and continuous independent variables
Variable
N
R
Age
1066
.038
Income
742
-.048
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P-value
.214
.193

ANOVA.
Counseling Adherence: Table 6 shows the results of ANOVAs conducted to explore the
impact of independent categorical variables on counseling adherence in mean weeks. There were
no statistically significant differences between the means of any of the personal characteristic
variables –gender, race, relationship status.
All of the socio-economic factors, with the exception of insurance, had no statistical
significance as well. There was a statistically significant difference in counseling adherence time
for the three insurance groups: F(2, 623)= 14.380, p=.000. Post hoc comparisons using the Tukey
HSD test indicated that the mean score for no insurance (M = 26.44, SD = 19.927) was
significantly different from public insurance (M = 35.72, SD = 19.567) but did not differ
significantly from private insurance (M = 27.29, SD = 19.938).
For the final personal factor, readiness to change was not statistically significant.
In regard to environmental influences, having a support system was not statistically
significant. There was a statistical significant difference in those who had integrated care and
those who did not: F(1, 623)= 6.256, p=.013.
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Table 6
ANOVA of Counseling Adherence and the categorical independent variables
Variable
N
Mean
SD
F
p-value
(weeks)
Gender
.926
.336
Male
226
31.77
19.945
Female
397
33.38
20.196
Race
.478
.620
White
539
32.57
20.274
Black/AA
32
36.14
18.199
Other
48
32.56
19.341
Relationship Status
.755
.470
Single
403
33.67
20.005
Married
97
32.30
20.103
Other
112
31.15
20.422
Education
.614
.653
< high school
132
34.49
19.865
High school
196
33.97
19.797
Vocational
18
33.93
21.261
Some college
78
30.68
19.904
College Degree
49
35.48
19.282
Employment
1.314
.269
Unemployed
263
32.29
20.102
Not-in workforce
116
34.91
20.075
Part-time
28
32.97
20.575
Full-time
69
37.19
17.645
Insurance
14.380
.000*
None
141
26.44
19.927
Public
421
35.72
19.567
Private
61
27.29
19.938
Readiness to Change
.891
.445
Pre-contemplation
169
32.70
20.637
Contemplation
201
34.48
19.971
Action
141
31.51
19.731
Maintenance
67
35.36
19.454
Support System
.231
.631
No
540
32.64
20.134
Yes
83
33.78
20.004
Integrated Care
6.256
.013*
No
339
30.96
20.603
Yes
284
34.99
19.300
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Variable

N

Drug Dependence
Prescriptions
352
Heroin
143
Crack/Cocaine
8
Methamphetamine
4
Other
8
Criminal History
No
429
Yes
69
Court. Ordered
No
487
Yes
28
Medications
Methadone
595
Buprenorphine
28
* Statistical significance, p  .05

Mean
(weeks)

SD

34.30
31.98
38.16
42.72
31.93

19.918
19.673
20.578
10.727
21.796

33.96
32.49

19.725
20.214

33.80
32.84

19.880
19.053

32.99
28.74

F

p-value

.673

.611

.328

.567

.061

.804

1.191

.276

20.293
15.297

Opioid Abstinence: Table 7 details the results of ANOVAs conducted to explore the
impact of independent categorical variables on opioid abstinence in mean days. There was no
statistical significance between the means of any of the personal characteristic variables –gender,
race, relationship status with opioid abstinence.
There was also no statistical significance for education. There was a statistical significant
difference in opioid abstinence days for the four employment groups: F(3, 820)= 3.2200, p=.022.
Post hoc comparisons using the Tukey HSD test indicated there was only one significant
difference between the four employment categories, unemployed patients (M = 135.39, SD =
128.336) and patients who worked full-time (M = 176.52, SD = 146.166).
Having some form of insurance had statistical significance with opioid abstinence: F(2,
1118)= 18.3700, p=.000. Post hoc comparisons using the Tukey HSD test indicated that the
mean score for no insurance (M = 109.32, SD = 114.748) was significantly different from public
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insurance (M = 151.32, SD = 135.362) and private insurance (M = 180.53, SD = 141.820).
However, there was no statistical significant difference in public and private insurance.
Readiness to change had no statistical significance with opioid abstinence.
For environmental influences, there was a statistically significant difference between
those who had social support: F(1, 1118)= 17.968, p=.000, and those who did not. In addition,
patients who received integrated care and those who did not had a statistical difference in opioid
abstinence days: F(1, 1118)= 11.763, p=.001.
Control variables indicated two significant differences between means in opioid
abstinence days. There was a statistical significant difference in primary drug dependence for the
five groups: F(4, 895)= 4.883, p=.001. Post hoc comparisons using the Tukey HSD test indicated
only two groups differed significantly from each other, prescription drugs (M = 148.41, SD =
133.448) and heroin (M = 117.10, SD = 122.836). Prescribed medications also indicated a
statistical significance between means for methadone and buprenorphine medications: F(1,
1118)= 43.986, p=.000.

Table 7
ANOVA Analysis of Opioid Abstinence and categorical independent variables
Variable
N Mean (days)
SD
F
Gender
.001
Male
419
139.28
134.524
Female
699
139.58
129.312
Race
.629
White
957
140.39
130.637
Black/AA
50
149.74
143.644
Other
100
126.96
132.193
Relationship Status
.096
Single
749
137.39
130.184
Married
164
139.17
134.662
Other
190
141.95
128.210
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p-value
.970

.533

.909

Variable
N
Education
< high school
244
High school
324
Vocational
28
Some college
140
College Degree
79
Employment
Unemployed
468
Not-in workforce
185
Part-time
45
Full-time
122
Insurance
None
387
Public
628
Private
103
Readiness to Change
Pre-contemplation
298
Contemplation
354
Action
250
Maintenance
119
Support System
No
972
Yes
146
Integrated Care
No
690
Yes
428
Drug Dependence
Prescriptions
610
Heroin
248
Crack/Cocaine
10
Methamphetamine
6
Other
21
Criminal History
No
707
Yes
155
Court. Ordered
No
837
Yes
58
Medications
Methadone
1067
Buprenorphine
51
* Statistical significance, p  .05

Mean (days)

SD

133.86
153.73
167.14
121.77
151.11

127.761
138.794
126.169
122.621
135.301

135.39
140.58
134.09
176.52
109.32
151.32
180.53
143.27
137.98
125.31
146.95

F
2.035

p-value
.088

3.220

.022*

18.370

.000*

1.136

.333

17.968

.000*

11.763

.001*

4.883

.001*

1.079

.299

1.280

.258

43.986

.000*

128.336
134.829
119.571
146.166
114.748
135.362
141.820
134.073
130.258
122.686
135.601

133.07
182.08

128.574
140.922

128.92
156.48

129.896
131.734

148.41
117.10
175.83
258.68
196.09

133.448
122.836
155.566
144.471
121.824

145.17
133.00

134.137
122.371

140.59
160.83

118.614
131.778

133.89
256.30

128.935
125.320
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Retention: Table 8 shows the results of ANOVAs conducted to explore the impact of
independent categorical variables on retention. There was no statistical significance between the
means of any of the personal characteristic variables -gender, race, relationship status- and socioeconomic variables -education, and employment- and retention, with the exception of insurance.
Insurance had a statistically significant difference in means for the three groups –none, public,
private: F(2, 1066)= 53.629, p=.000. Post hoc comparisons using the Tukey HSD test indicated
that the mean score for no insurance (M = 146.71, SD = 123.167) was significantly different
from public insurance (M = 233.15, SD = 133.145) and private insurance (M = 234.09, SD =
138.778). However, there was no statistically significant difference in public and private
insurance.
Readiness to change had no statistical significance with retention.
There was a statistically significant difference in those who had a support system F(1,
1066)= 9.561, p=.002, and those who did not. In addition, patients who received integrated care
and those who did not had a statistical difference between means in opioid abstinence days (1,
1118)= 71.975, p=.000.
Control variables indicated two significant differences between means in retention days.
There was a statistically significant difference in patients who had a criminal history and those
who did not: F(1, 822)= 4.703, p=.030. Prescribed medications also indicated a statistical
significance between means for methadone and buprenorphine: F(1, 1066)= 19.078, p=.000.
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Table 8
ANOVA Analysis of Retention in treatment and categorical independent variables
Variable
N Mean (days)
SD
F
Gender
.095
Male
387
201.20
133.874
Female
679
203.88
138.094
Race
2.781
White
923
204.81
137.144
Black/AA
45
225.51
127.292
Other
87
173.17
130.894
Relationship Status
.286
Single
720
200.78
136.946
Married
155
209.14
136.607
Other
179
198.86
133.223
Education
1.464
< high school
234
200.15
133.099
High school
306
218.41
135.657
Vocational
26
206.69
130.950
Some college
135
191.84
128.442
College Degree
74
225.53
141.998
Employment
1.337
Unemployed
453
200.79
133.952
Not-in workforce
175
217.51
136.563
Part-time
43
231.02
131.646
Full-time
109
217.70
132.260
Insurance
None
374
146.71
123.167
53.629
Public
600
233.15
133.145
Private
92
234.09
138.778
Readiness to Change
.837
Pre-contemplation
286
201.60
137.417
Contemplation
335
200.25
135.946
Action
241
200.77
133.300
Maintenance
117
221.98
136.599
Support System
9.561
No
924
197.83
137.648
Yes
142
235.91
124.419
Integrated Care
71.975
No
660
175.97
138.729
Yes
406
246.70
120.786
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p-value
.758

.062

.751

.211

.261

.000*

.474

.002*

.000*

Variable
N
Drug Dependence
Prescriptions
587
Heroin
232
Crack/Cocaine
10
Methamphetamine
5
Other
20
Criminal History
No
668
Yes
154
Court. Ordered
No
796
Yes
58
Medications
Methadone
1031
Buprenorphine
35
* Statistical significance, p  .05

Mean (days)

SD

208.37
200.08
242.70
316.00
223.35

137.150
127.613
145.924
109.567
133.992

212.29
186.27

F
1.236

p-value
.294

4.703

.030*

1.716

.191

19.078

.000*

133.766
136.041

205.87
229.84

135.435
121.496

199.57
301.20

136.067
112.458

Survival Analysis
Kaplan Meier Method.
The Kaplan-Meier survival curves of the treatment outcomes are illustrated only for
selected factors with significant associations and the detailed results are included in Table 9. For
each covariate the table includes the percentage for each category that met the survival goal (52
weeks or 365 days), the median survival time, chi-square, and significance. The Log rank
(Mantel-cox) was used for the chi-square, since it focuses on events that occur later on within the
timeframe (Kleinbaum & Klein, 2005). Since none of the curves were normal for the dependent
variables, the median (versus the mean) was used for the estimated survival time rounded to the
nearest whole number (Barker, 2009).
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Table 9
Kaplan Meier table of covariates and treatment outcomes.
Counseling
Opioid Abstinence
Retention
Adherence
Gender
Male
38.9%, est. 34 weeks
17.9%, est. 66 days 29.7%, est. 180 days
Female
46.1%, est. 42 weeks
16.7%, est. 79 days 33.07%, est. 183 days
2
x (1, N=623)=
x2 (1, N=1118)=
x2 (1, N=1066)=
2.230, p=.135
.037, p=.848
.473, p=.492
Race
White
43.4%, est. 38 weeks
16.8%, est. 79 days 32.5%, est. 184 days
Black/AA
50.0%, est. 43 weeks
22.0 %, est.62 days 33.3%, est. 209 days
Other
37.5%, est. 36 weeks
19.0%, est. 50 days 24.1%, est. 132 days
x2
x2 (2, N= 619)=
x2 (2, N= 1107) =
(2, N=1055)=
1.055, p=.590
.583, p= .747
4.608, p= .100
Relationship Status
Single
45.7%, est. 42 weeks
16.6%, est. 75 days 31.3%, est. 176 days
Married
42.3%, est. 33 weeks
20.1%, est. 78 days 34.8%, est. 194 days
Other
40.2%, est. 34 weeks
14.2%, est. 85 days 27.9%, est. 175 days
x2 (2, N= 612)=
x2 (2, N= 1103)=
x2 (2, N= 1054)=
1.464, p= .481
.157, p= .924
1.131, p=.568
Education
< high school
50.0%, est. 47 weeks
15.2%, est. 73 days 29.1%, est. 175 days
High school
46.4, est. 43 weeks
22.5%, est. 90 days 37.6%, est. 222 days
Vocational
50.0, est. 44 weeks 17.9%, est. 165 days 26.9%, est. 196 days
Some college
37.2, est. 26 weeks
12.9%, est. 62 days 24.4%, est. 176 days
College Degree
42.9, est. 47 weeks 16.5%, est. 109 days 37.8%, est. 260 days
x2 (4, N=473)=
x2 (4, N= 815)=
x2 (4, N= 775)=
3.190, p= .527
8.174, p= .085
8.514, p= .074
Employment
Unemployed
43.7%, est. 36 weeks
16.7%, est. 73 days 30.2%, est. 178 days
Not-in workforce
47.4%, est. 48 weeks
17.8%, est. 74 days 36.0%, est. 229 days
Part-time
50.0%, est. 35 weeks 11.1%, est. 118 days 41.9%, est. 212 days
Full-time
47.8%, est. 48 weeks 26.2%, est. 119 days 32.1%, est. 234 days
x2 (3, N= 476)=
x2 (3, N= 820)=
x2 (3, N= 780)=
1.673, p= .643
7.271, p= .064
3.982, p= .263
Insurance
None
28.4%, est. 24 weeks
9.6%, est. 52 days
14.2%, est. 93 days
Public
50.8%, est. 33 weeks
20.2%, est. 91days 41.3%, est. 261 days
Private
27.9%, est. 27 weeks 27.2%, est. 164 days 41.3%, est. 307 days
x2 (2, N= 623)=
x2 (2, N= 1118)=
x2 (2, N= 1066)=
33.641, p= .000*
37.823, p= .000*
120.975, p= .000*
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Counseling
Adherence

Opioid Abstinence

Retention

45.0%, est. 43 weeks
48.3%, est. 49 weeks
37.6%, est. 33 weeks
50.7%, est. 35 weeks
x2 (3, N= 578)=
4.189, p= .242

18.8%, est. 77 days
17.5%, est. 73 days
12.4%, est. 73 days
19.3%, est. 82 days
x2 (3, N= 1021)=
4.509, p= .211

32.5%, est. 178 days
32.5%, est. 172 days
28.6%, est. 183 days
35.9%, est. 245 days
x2 (3, N= 979)=
1.986, p= .575

43.3%, est. 38 weeks
44.6%, est. 43 weeks
x2 (1, N= 623)=.116,
p= .733

15.7%, est. 70 days
26.7%, est. 170 days
x2 (1, N= 1118)=
13.297, p= .000*

31.2%, est. 170 days
35.9%, est. 242 days
x2 (1, N= 1066)=
4.859, p= .028*

39.8%, est. 32 weeks
47.9%, est. 44 weeks
x2 (1, N= 623)=
5.548, p= .019*

15.9%, est. 64 days
19.2%, est. 108 days
x2 (1, N= 1118)=
9.370, p= .002*

26.5%, est. 122 days
40.4%, est. 275 days
x2 (1, N= 1066)=
48.188, p= .000*

47.7%, est. 48 weeks
38.5%, est. 33 weeks
62.5%, est.
weeks
50.0%, est. 34 weeks
50.0%, est. 16 weeks
x2 (4, N= 515)=
3.793, p= .435

19.3%, est. 85 days
12.1%, est. 51 days
30.0%, est. 79 days
50.0%, est. 300 days
23.8%, est. 202 days
x2 (4, N= 895)=
19.255, p= .001*

34.2%, est. 194 days
25.0%, est. 183 days
50.0%, est. 281 days
80.0%, est.
days
40.0%, est. 201 days
x2 (4, N= 854)=
7.758, p= .101

45.7%, est. 43 weeks
42.0%, est. 35 weeks
x2 (1, N= 498)= .355,
p= .551

18.8%, est. 81 days
14.2%, est. 83 days
x2 (1, N= 862)= .993,
p= .319

33.4%, est. 208 days
26.6%, est. 160 days
x2 (1, N= 822)=
4.598, p= .032*

45.6%, est. 43 weeks
42.9%, est. 34 weeks
x2 (1, N= 515)= .046,
p= .830

17.9%, est. 78 days
15.5%, est. 134 days
x2 (1, N= 895)= .720,
p= .396

32.3%, est. 194 days
32.8%, est. 183 days
x2 (1, N= 854)= .589,
p= .443

45.0%, est. 41 weeks
10.7%, est. 28 weeks
x2 (1, N= 623)=
7.374, p= .007*
* Statistical significance, p  .05

16.1%, est.72 days
39.2%, est. 322 days
x2 (1, N= 1118)=
22.430, p= .000*

30.9%, est.176 days
57.1%, est. days
x2 (1, N= 1066)=
10.921, p= .001*

Readiness to Change
Pre-contemplation
Contemplation
Action
Maintenance

Support System
No
Yes

Integrated Care
No
Yes

Drug Dependence
Prescriptions
Heroin
Crack/Cocaine
Methamphetamine
Other

Criminal History
No
Yes

Court. Ordered
No
Yes

Medication
Methadone
Buprenorphine
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There were no statistically significant associations with personal characteristics and
treatment outcomes. Health insurance was the only socio-economic factor which showed an
association with all three dependent variables. Figures 6, 7 and 8 show the curve of counseling
adherence, opioid abstinence and retention respectively by health insurance. Relative to
counseling adherence, patients with public coverage have a higher survival probability than those
with private or no insurance (Log-rank statistic = 33.641, p = .000). Opioid abstinence on the
other hand, initially showed a similar probability among all three categories in the first 50 days.
However, as time progressed, those with private coverage had a higher probability than those
with public assistance, followed by those with no insurance with the lowest survival probability
to abstain from opioids (Log-rank statistic = 37.823, p = .000). Patients’ retention in treatment
was higher if they had either public or private insurance than if they had none. (Log-rank statistic
= 120.975, p = .000). Median survival time was over 240 days for patients with either type of
insurance (public= 261 days, private= 307 days) versus 93 days for patients without insurance.

62

Figure 6. Insurance and Counseling Adherence. This figure illustrates the Kaplan Meier survival
curve on the association of insurance and counseling adherence.

Figure 7. Insurance and Opioid Abstinence. This figure illustrates the Kaplan Meier survival
curve on the association of insurance and opioid abstinence.
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Figure 8. Insurance and Retention. This figure illustrates the Kaplan Meier survival curve on the
association of insurance and retention.

For environmental influences, there were associations for both covariates. There was a
statistically significant association with social support and two of the dependent variables-opioid
abstinence and retention. Figure 9 illustrates patients with social support having a higher survival
probability than those without, in abstaining from opioids (Log-rank statistic = 13.297, p = .002).
The median survival time was 170 days for those with social support versus those without social
support at 70 days. Similarly, a higher probability in survival time was seen in relation to
retention and having social support. Figure 10 shows the survival probability for patients with
social support having a higher survival probability than those without in relation to retention
(Log-rank statistic = 4.859, p = .028). The median survival time was 242 days for those with
social support versus those without social support at 170 days.
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Figure 9. Social Support and Opioid Abstinence. This figure illustrates the Kaplan Meier
survival curve on the association of support systems and opioid abstinence.

Figure 10. Social Support and Retention. This figure illustrates the Kaplan Meier survival curve
on the association of support systems and retention.
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Integrated care showed statistically significant associations with all dependent variables.
Figures 11, 12, and 13 depicts the association of integrated care on counseling adherence, opioid
abstinence and retention respectively in Kaplan Meier curves. In regard to counseling adherence,
patients with integrated care have a higher survival probability than those without (Log-rank
statistic = 5.548, p = .019). Opioid abstinence on the other hand, initially showed a similar
probability among both categories in the initial month as seen in Figure 12. However, as time
progressed those with integrated care had a higher probability than those without (Log-rank
statistic = 9.370, p = .002). Patients’ retention in treatment had a much higher survival
probability if they were in integrated care than not (Log-rank statistic = 48.188, p = .000).
Median survival time of those with integrated care was 275 days versus 122 days for those
without integrated care.

Figure 11. Integrated Care and Counseling Adherence. This figure illustrates the Kaplan Meier
survival curve on the association of integrated care and counseling adherence.
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Figure 12. Integrated Care and Opioid Abstinence. This figure illustrates the Kaplan Meier
survival curve on the association of integrated care and opioid abstinence.

Figure 13. Integrated Care and Retention. This figure illustrates the Kaplan Meier survival curve
on the association of integrated care and retention.
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Finally, the control variables had three significant associations. The association of opioid
abstinence and primary drug dependence showed a statistically significant association, as
depicted in Figure 14. Those whose primary dependence was methamphetamine or other drugs
have a higher survival probability in comparison to non-medicinal prescription drugs (median
survival: 85 days) or heroin (median survival: 51 days) (Log-rank statistic = 19.255, p = .001).

Figure 14. Primary Drug Dependence and Opioid Abstinence. This figure illustrates the Kaplan
Meier survival curve on drug dependence and opioid abstinence.

Those with no criminal history had a median survival of 208 days retained in MAT in
comparison with 160 days for those with a criminal (Log-rank statistic = 4.598, p = .032). Figure
15 shows the association of patient’s criminal history and retention.
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Figure 15. Criminal History and Retention. This figure illustrates the Kaplan Meier survival
curve on the association of criminal history and retention.

All dependent variables had an association of significance with the medication
prescribed. Figure 16 shows patients on methadone having a higher survival probability than
those on buprenorphine for counseling adherence (Log-rank statistic = 7.374, p = .007). The
median survival time was 41 weeks for methadone in comparison to 28 weeks for
buprenorphine. Alternatively, buprenorphine had a higher survival probability than methadone in
relation to opioid abstinence as seen in Figure 17 (Log-rank statistic = 22.430, p = .000), and also
in relation to retention in treatment (Log-rank statistic = 10.921, p = .001 which is illustrated in
Figure 18.
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Figure 16. Medication Prescribed and Counseling Adherence. This figure illustrates the Kaplan
Meier survival curve on the association of medication prescribed and counseling adherence.

Figure 17. Medication Prescribed and Opioid Abstinence. This figure illustrates the Kaplan
Meier survival curve on medication prescribed and opioid abstinence.
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Figure 18. Medication Prescribed and Retention. This figure illustrates the Kaplan Meier
survival curve on the association of medication prescribed and retention.

Multicollinearity Assumption.
All independent variables were analyzed for multicollinearity to ensure predictor
variables did not impact the conclusions derived from the Cox regression model. Variance
Inflation Factors (VIFs) reveal how many times a coefficient's standard error is increased due to
collinearity (O'brien, 2007). VIFs higher than four means collinearity does exist. Collinearity
diagnostics were analyzed for the independent variables, all of which were below two.
Additionally, the standard errors in the cox regression models (reported next) for all variables
were small (Chan, 2004). Multicollinearity did not exist between the independent variables
included in the models.
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Cox Regression Analysis.
To assess the relationship of personal factors and environmental influences on the
dependent variables (counseling adherence, opioid abstinence, and retention) while controlling
for factors such as primary drug dependence, criminal history, court-ordered treatment and
medication prescribed, three cox regression models (one for each of the dependent variables)
were observed. All three models were statistically significant. In the cox regression analyses
tables (10, 11 and 12), the exponentiated coefficients (Exp B) are the hazard ratios. The hazard
ratio describes the relationship between the covariates and survival time. It is the measure of
effect inferred in a survival analysis (Kleinbaum & Klein, 2005). If the hazard ratio numerical
value is less than one, with the confidence interval less than one, it means the covariate decreases
failure (increases the likelihood of survival time). A hazard ratio of one means there is no
relationship between the covariates and dependent variables. A hazard ratio greater than one,
with the confidence interval above one, means the covariate has a higher risk of failure
(decreasing the survival time).
Counseling Adherence: In the first model, the analysis is detailed in Table 10 and the
survival curve depicting the number of weeks patients in treatment adhered to counseling over a
12-month period is shown in Figure 19. The model’s summary statistics indicate the model was
strong explaining factors influencing counseling adherence as the model was statistically
significant (x2= 48.527, p .05).
The results indicate that age was the only significant (p.05) personal characteristic
factor when controlling for other variables. An increase in age is associated with being more
likely to adhere to counseling (HR=.968, 95% CI= .950-.986, p= .001).
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For socio-economic factors, statistically significant associations were observed in relation
to the employment and insurance variables. Patients not-in-the-workforce (i.e. student, homemaker, disabled) (HR= 1.508, 95% CI= 1.026 - 2.218, p= .037) were more likely than those
unemployed to not continue adhering to counseling sessions. Those without insurance (HR=
1.000, p= .000) and public coverage (HR= .489, CI= .342 - .698, p= .000) were predictors of
adhering to counseling. Education did not have a significant association in determining
counseling adherence while controlling for other factors.
The final personal factor, readiness to change, was not statistically significant. However,
although not significant the model indicated those in action stage have a higher risk of shorter
counseling adherence (HR= 1.476, CI= .987- 2.208, p= .058) than those in pre-contemplation.
Neither of the environmental factors showed statistical significance while controlling for
other factors.
The controlling variables -criminal history, court-ordered, medication prescribed- did not
have statistical significance with the exception of primary drug dependence. Having a primary
drug dependence of heroin showed a higher risk of shorter counseling adherence (HR= 1.514,
CI= 1.097 - 2.090, p= .012) than patients whose primary dependence is non-medicinal
prescription drugs.
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Table 10
Cox regression predicting number of weeks adhering to counseling in treatment
95.0% CI
Exp (B)
Lower
Upper
Gender
Male (ref)
1.000
Female
.920
.648
1.307
Race
White (ref)
1.000
Black/AA
1.299
.630
2.680
Other
1.203
.708
2.044
Age
.968
.950
.986
Relationship Status
Single (ref)
1.000
Married
.939
.609
1.449
Other
1.346
.902
2.009
Education
Less than high school diploma(ref)
1.000
High school diploma/GED
1.227
.847
1.778
Vocational
1.403
.625
3.154
Some college
1.463
.921
2.322
College degree
.962
.572
1.615
Employment
Unemployed (ref)
1.000
Not-in workforce
1.508
1.026
2.218
Part-time
.666
.357
1.243
Full-time
.710
.441
1.143
Income
1.000
1.000
1.000
Insurance
None (ref)
1.000
Public
.489
.342
.698
Private
.682
.392
1.188
Readiness to Change
Pre-contemplation (ref)
1.000
Contemplation
.998
.682
1.461
Action
1.476
.987
2.208
Maintenance
1.229
.732
2.064
Support System
No (ref)
1.000
Yes
1.129
.727
1.753
Integrated Care
No (ref)
1.000
Yes
.806
.591
1.100
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Sig.

.643
.641
.479
.494
.001*
.273
.777
.145
.439
.279
.412
.107
.882
.023*
.037*
.202
.158
.145
.000*
.000*
.177
.154
.993
.058
.435

.588

.174

95.0% CI
Lower

Exp (B)
Drug Dependence
Prescription drugs (ref)
Heroin
Crack/Cocaine
Methamphetamine
Other
Criminal History
No (ref)
Yes
Court Ordered
No (ref)
Yes
Medication
Methadone (ref)
Buprenorphine
Summary Statistics
-2 Log Likelihood
Model (x2)
Degrees of freedom
P-value
* Statistical significance, p  .05

Upper

Sig.

1.000
1.514
.508
.326
.696

1.097
.119
.042
.201

2.090
2.162
2.519
2.403

.056
.012*
.359
.282
.566

1.000
.754

.440

1.292

.304

1.000
1.295

.656

2.558

.456

1.000
1.033

.390

2.739

.948
2143.365
48.527
28
.009
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Figure 19. Counseling Adherence survival curve. This figure illustrated the survival curve of
number of weeks adhering to counseling over 12 months.

Opioid Abstinence: The results for the second cox regression model analysis is described
in Table 11, and the survival curve depicting the number of days patients abstained from opioids
is illustrated in Figure 20. The model’s summary statistics indicate the model was strong
explaining factors influencing opioid abstinence as the model was statistically significant (x2=
78.961, p .05).
No statistically significant associations were seen between personal characteristics in
relation to opioid abstinence, while controlling for other factors; the p-values were insignificant.
Opioid abstinence at 365 days was predicted by two socio-economic factors, employment
and insurance. Patients with full-time employment (HR= .734, 95% CI=.544 - .991, p=.043)
were more likely to abstain from opioids at 365 days than those unemployed. Patients receiving
public coverage (HR= .652, 95% CI= .529 - .804, p= .000) and those with private insurance
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(HR= .685, 95% CI= .483 - .973, p= .035) were more likely to abstain from opioids than those
without insurance (HR= 1.000, p= .000).
Readiness to change had surprising results when controlling for other factors. Patients in
action phase (HR= 1.316, 95% CI= 1.028 - 1.686, p= .029), the only statistically significant
category, were less likely to abstain from opioids at 365 days than those in pre-contemplation.
The two environmental factors, having a support system and receiving integrated care
were both statistically significant. Patients who reported having a support system (HR= .716,
95% CI= .537 - .954, p= .022) at intake were more likely to abstain from opioids. Similarly,
patients receiving integrated care (HR= .802, 95% CI= .660 - .975, p= .027) were also more
likely to abstain from opioids at 365 days.
The controlling variables did not have statistical significance with the exception of
primary drug dependence. Patients with a primary drug dependence of heroin were less likely to
abstain from opioids (HR= 1.480, 95% CI= 1.209 - 1.811, p= .000) than patients whose primary
dependence is non-medicinal prescription drugs (HR= 1.000, p= .002).
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Table 11
Cox regression, predicting number of days abstaining from opioids
95.0% CI
Exp (B)
Lower
Gender
Male (ref)
1.000
Female
.936
.757
Race
White (ref)
1.000
Black/AA
.892
.538
Other
.992
.709
Age
.998
.987
Relationship Status
Single (ref)
1.000
Married
.914
.687
Other
.953
.736
Education
Less than high school diploma(ref)
1.000
High school diploma/GED
.819
.659
Vocational
.908
.561
Some college
1.031
.784
College degree
.920
.671
Employment
Unemployed (ref)
1.000
Not-in workforce
1.095
.855
Part-time
1.023
.710
Full-time
.734
.544
Income
1.000
1.000
Insurance
None (ref)
1.000
Public
.652
.529
Private
.685
.483
Readiness to Change
Pre-contemplation (ref)
1.000
Contemplation
1.071
.849
Action
1.316
1.028
Maintenance
1.210
.886
Support System
No (ref)
1.000
Yes
.716
.537
Integrated Care
No (ref)
1.000
Yes
.802
.660
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Upper

Sig.

1.159

.546

1.478
1.388
1.009

.906
.657
.963
.735

1.216
1.234

.810
.538
.715

1.018
1.469
1.357
1.261

.351
.072
.693
.827
.605

1.403
1.474
.991
1.000

.128
.471
.904
.043*
.497

.804
.973

.000*
.000*
.035*

1.351
1.686
1.651

.140
.562
.029*
.230

.954

.022*

.975

.027*

95.0% CI
Lower

Exp (B)
Drug Dependence
Prescription drugs (ref)
Heroin
Crack/Cocaine
Methamphetamine
Other
Criminal History
No (ref)
Yes
Court Ordered
No (ref)
Yes
Medication
Methadone (ref)
Buprenorphine
Summary Statistics
-2 Log Likelihood
Model (x2)
Degrees of freedom
P-value
* Statistical significance, p  .05

Upper

Sig.

1.000
1.480
.834
.471
.752

1.209
.335
.114
.387

1.811
2.074
1.941
1.463

.002*
.000*
.696
.297
.401

1.000
1.192

.904

1.570

.214

1.000
.905

.606

1.351

.625

1.000
.581

.298

1.133

.111
5755.786
78.961
28
.000

Figure 20. Opioid Abstinence Survival Curve. This figure illustrated the survival curve of
number of days abstaining from opioids over 12 months.
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Retention: the final cox regression analysis results are indicated in Table 12, and the
survival curve depicting the number of days patients retained in treatment is illustrated in Figure
21. The model’s summary statistics indicate the model was strong explaining factors influencing
opioid abstinence as the model was statistically significant (x2= 144.174, p .05).
Retention at 365 days was predicted by a number of factors, while controlling for
patients’ primary drug dependence, criminal history, being court-ordered to treatment, and
medication prescribed. For personal characteristics, an increase in age was associated with
patients being more likely to still be in treatment at one year (HR= .985, 95% CI= .972 - .999, p=
.034). Race was the other statistically significant personal characteristic. Patients under other
(not White or African American/Black) were less likely than Whites to still be in treatment at
365 days (HR= 1.455, 95% CI= 1.000 – 2.118, p= .050).
For socio-economic factors, statistically significant associations were seen in all factors
with the exception of income. Patients who had a high school diploma/GED (HR= .760, 95%
CI= .593 - .976, p= .031) were more likely to still be in treatment at one year than those whose
highest education level attainment was less than a diploma. Patients working part-time (HR=
.615, 95% CI= .390 - .972, p= .037) were more likely to still be in treatment at one year than
those unemployed (p= .028). Although not significant, the model indicated patients having fulltime employment (HR.723, p= .061) were also more likely to still be in treatment at one year
than those unemployed. Those with insurance -public coverage (HR= .399, 95% CI= .315 - .505,
p= .000) and private insurance (HR= .496, 95% CI= .337 - .731, p= .000)- were more likely than
those without health insurance to still be in treatment at one year (HR= 1.000, p= .000).
Again, readiness to change had unexpected results when controlling for other factors.
Patients in action phase (HR= 1.454, 95% CI= 1.093 - 1.934, p= .010), the only statistically
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significant category, were less likely to be in treatment after one year than those in precontemplation.
Having a support system did not have a significant role in determining retention. On the
other hand, receiving integrated care (HR= .564, 95% CI= .450 - .709, p= .000) was a predictor
of retaining in treatment.
The controlling variables did not have statistical significance with the exception of
primary drug dependence. Patients with a primary drug dependence of heroin were less likely to
still be in treatment at 365 days (HR= 1.370, 95% CI= 1.086 - 1.727, p= .008) than those whose
primary dependence was prescription drugs (HR= 1.000, p= .016).

Table 12.
Cox regression, predicting number of days retained in treatment.
95.0% CI
Exp (B)
Lower
Gender
Male (ref)
1.000
Female
1.126
.882
Race
White (ref)
1.000
Black/AA
.997
.555
Other
1.455
1.000
Age
.985
.972
Relationship Status
Single (ref)
1.000
Married
.804
.577
Other
1.049
.778
Education
Less than high school diploma(ref)
1.000
High school Diploma/GED
.760
.593
Vocational
.981
.570
Some college
.992
.729
College Degree
.780
.539
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Upper

Sig.

1.437

.341

1.791
2.118
.999

.146
.991
.050*
.034*

1.122
1.415

.357
.199
.753

.976
1.689
1.350
1.127

.172
.031*
.946
.958
.186

95.0% CI
Lower

Exp (B)
Employment
Unemployed (ref)
Not-in workforce
Part-time
Full-time
Income
Insurance
None (ref)
Public
Private
Readiness to Change
Pre-contemplation (ref)
Contemplation
Action
Maintenance
Support System
No (ref)
Yes
Integrated Care
No (ref)
Yes
Drug Dependence
Prescription Drugs (ref)
Heroin
Crack/Cocaine
Methamphetamine
Other
Criminal History
No (ref)
Yes
Court Ordered
No (ref)
Yes
Medication
Methadone (ref)
Buprenorphine
Summary Statistics
-2 Log Likelihood
Model (x2)
Degrees of freedom
P-value
* Statistical significance, p  .05

Upper

Sig.

1.000
1.166
.615
.723
1.000

.879
.390
.515
1.000

1.545
.972
1.015
1.000

.028*
.286
.037*
.061
.107

1.000
.399
.496

.315
.337

.505
.731

.000*
.000*
.000*

1.000
1.268
1.454
1.201

.964
1.093
.848

1.669
1.934
1.700

.079
.089
.010*
.303

1.000
.832

.605

1.144

.564

1.000
.564

.450

.709

.000*

1.000
1.370
.675
.348
.539

1.086
.211
.048
.244

1.727
2.167
2.534
1.190

.016*
.008*
.509
.297
.126

1.000
1.243

.922

1.674

.153

.836

.532

1.312

.436

1.000
.709

.330

1.520

.376
4457.881
144.174
28
.000
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Figure 21. Retention Survival Curve. This figure illustrated the survival curve of number of days
retained in treatment over 12 months.

Conclusions of Hypothesis Testing
Each hypothesis included sub-hypotheses as it related to each of the dependent variables counseling adherence, opioid abstinence, and retention in MAT.
Personal Factors.
Personal characteristics. Variables in this category included: gender, race, age and
relationship status.
Hypothesis 1A: Gender – identification as male is negatively associated with treatment
outcomes.
H1ACA: Male gender is negatively associated with treatment counseling adherence.
H1AOA: Male gender is negatively associated with abstinence from opioids.
H1AR: Male gender is negatively associated with retention in treatment.
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This study divided patients into male and female categories, with males being the
reference variable. The sample was predominantly female, with only 38.6% of male patients.
The ANOVA revealed the means between males and females were not significantly different
from one another as did the Kaplan Meier Method (included the mean and median, since none of
the curves were normally distributed) for all three dependent variables. Furthermore, all three
cox regression models were not statistically significant for gender, H1ACA, H1AOA, and H1AR
were not supported.

Hypothesis 1B: Race - identification as African American is negatively associated with treatment
outcomes.
H1BCA: Identification as African American is negatively associated with treatment counseling
adherence.
H1BOA: Identification as African American is negatively associated with abstinence from
opioids.
H1BR: Identification as African American is negatively associated with retention in treatment.
The sample characteristics showed that only a small percentage (4.5%) of patients were
African American/Black. The bivariate associations between race and counseling adherence,
opioid abstinence, and retention were all statistically insignificant. The cox regression analyses
were also statistically insignificant with the exception of patients in the other category being less
likely to still be in treatment at 365 days. Therefore H1BCA, H1BOA, and H1BR were not
supported.
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Hypothesis 1C: Age is positively associated with treatment outcomes.
H1CCA: Age is positively associated with treatment counseling adherence.
H1COA: Age is positively associated with abstinence from opioids.
H1CR: Age is positively associated with retention in treatment.
Bivariate associations between age and each treatment outcome were all statistically nonsignificant. However, when controlling for additional factors, an increase in age is associated
with being more likely to adhere to counseling at one year. This variable was a statistically
significant predictor. Age was not significant in the opioid abstinence model. For the retention
model, the association was statistically significant, showing an increase in age was associated
with being more likely to retain in treatment at one year. Therefore, H1CCA and H1CR were
supported, and H1COA was not supported.

Hypothesis 1D: Single relationship status is positively associated with treatment outcomes.
H1DCA: Single - relationship status is positively associated with treatment counseling adherence.
H1DOA: Single - relationship status is positively associated with abstinence from opioids.
H1DR: Single - relationship status is positively associated with retention in treatment.
Bivariate analyses did not indicate any statistically significant associations with
relationship status. The cox regression analyses were also all not statistically significant. H1DCA,
H1DOA, and H1DR were not supported.
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Hypothesis 2A: Higher education is positively associated with successful treatment outcomes in
MAT patients.
H2ACA: Higher education is positively associated with treatment counseling adherence.
H2AOA: Higher education is positively associated with abstinence from opioids.
H2AR: Higher education is positively associated with retention in treatment.
The ANOVA analyses did not demonstrate any statistically significant difference in
means between the education groups in each of the time dependent variables, as well as the chisquare analyses in the Kaplan Meier model. The likelihood of still being retained in treatment
differed across education levels, and most of the cox regression analyses also showed no
statistically significant association between education and the dependent variables. The retention
analysis however, did have a significant relationship between patients with a high school
diploma/GED being more likely to be retained in treatment at one year. However, no
significance was indicated with an increase in education, therefore H2ACA, H2AOA, and H2AR
were all not supported.

Hypothesis 2B: Employment is positively associated with successful treatment outcomes in
MAT patients.
H2BCA: Employment is positively associated with treatment counseling adherence.
H2BOA: Employment is positively associated with abstinence from opioids.
H2BR: Employment is positively associated with retention in treatment.
Two ANOVA analyses did not demonstrate any statistically significant difference in
means between the employment groups for the counseling adherence and retention dependent
variables. There was a statistically significant difference between the unemployment and full-
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time employment means in the opioid abstinence ANOVA. Additionally, the cox regression
analysis also had a statistically significant association of patients with full-time employment
being more likely to abstain from opioids at 365 days than those unemployed. In the counseling
adherence cox regression analysis unemployed and not-in-the-work force had significant
associations, with those not-in-the-workforce less likely than those unemployed to be in
counseling at one year. The retention cox regression showed patients who worked part-time were
more likely to still be in treatment at one year than those unemployed. H2BCA is therefore not
supported, whereas H2BOA is supported for full-time employment, and H2BR is supported for
part-time employment.

Hypothesis 2C: Having a higher income is positively associated with successful treatment
outcomes in MAT patients.
H2CCA: Higher income is positively associated with treatment counseling adherence.
H2COA: Higher income is positively associated with abstinence from opioids.
H2CR: Higher income is positively associated with retention in treatment.
Correlations revealed no significant associations between income and any of the
dependent variables. The three cox regression analyses also revealed no significant associations
with income, H2CCA, H2COA, and H2CR were not supported.

Hypothesis 2D: Having health insurance is positively associated with successful treatment
outcomes in MAT patients.
H2DCA: Having health insurance is positively associated with treatment counseling adherence.
H2DOA: Having health insurance is positively associated with abstinence from opioids.
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H2DR1: Having health insurance is positively associated with retention in treatment.
H2DR2: Having public insurance (Medicaid) is positively associated with retention in treatment.
Bivariate analyses -both ANOVA and Kaplan Meier survival curves- illustrated
statistically significant associations between insurance and treatment outcomes. When
controlling for additional variables in the cox regression analyses the associations were also
statistically significant. Only public insurance (not private) did show a statistical significance
with counseling adherence; patients being more likely to still be in counseling at one year than
those without insurance. Both insurance groups did indicate being more likely to abstain from
opioids and retained in treatment at one year. All four hypotheses were supported H2DCA,
H2DOA, and H2DR, and H2DR2. H2DCA was supported only for public insurance.

Hypothesis 3A: Readiness to change is positively associated with treatment outcomes in MAT
patients.
H3ACA: Readiness to change is positively associated with treatment counseling adherence.
H3AOA: Readiness to change is positively associated with abstinence from opioids.
H3AR: Readiness to change is positively associated with retention in treatment.
None of the bivariate analyses had statistically significant associations between the
readiness to change categories and dependent variables. The cox regression opioid abstinence
and retention models did show significance for the action category, but in the opposite direction.
Patients in the action phase were less likely to abstain from opioids and still be in treatment at
one year. None of the other categories showed significant results, H3ACA, H3AOA, and H3AR
were not supported.
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Environmental Influences.
Hypothesis 4A: Having social support during treatment is positively associated with treatment
outcomes in MAT patients.
H4ACA: Having social support is positively associated with treatment counseling adherence.
H4AOA: Having social support is positively associated with abstinence from opioids.
H4AR: Having social support is positively associated with retention in treatment.
All counseling adherence analyses -ANOVA, Kaplan Meier, and Cox regression- were
all not statistically significant. Conversely, all opioid abstinence models were statistically
significant indicating patients reporting social support at intake were more likely to abstain from
opioids at one year. Retention models were statistically significant with bivariate relationships,
but insignificant when controlling for other factors in the cox model. H4ACA and H4AR were not
supported, whereas H4AOA was supported.

Hypothesis 5A: Patients receiving integrated care are associated with positive treatment
outcomes in MAT.
H5ACA: Receiving integrated care is positively associated with treatment counseling adherence.
H5AOA: Receiving integrated care is positively associated with opioid abstinence.
H5AR: Receiving integrated care is positively associated with retention in treatment.
All bivariate analyses were statistically significant. However, when controlling for other
factors, there was no statistically significant association with counseling adherence. In regard to
the other two dependent variables, patients receiving integrated care were more likely to abstain
from opioids and retain in treatment at one year. Therefore, H5AOA and H5AR were supported,
and H5ACA was not supported.
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Table 13 provides a Hypothesis Testing Summary of the above section, which
demonstrates whether a hypothesis was supported or not, indicated by an “X” as a result of the
cox regression analyses.

Table 13
Hypothesis Testing Summary
Hypothesis

Supported

H1ACA: Male gender is negatively associated with treatment
counseling adherence.
H1AOA: Male gender is negatively associated with abstinence from
opioids.
H1AR: Male gender is negatively associated with retention in
treatment
H1BCA: Identification as African American is negatively associated
with treatment counseling adherence.
H1BOA: Identification as African American is negatively associated
with abstinence from opioids.
H1BR: Identification as African American is negatively associated
with retention in treatment.
H1CCA: Age is positively associated with treatment counseling
adherence.
H1COA: Age is positively associated with abstinence from opioids.
H1CR: Age is positively associated with retention in treatment.
H1DCA: Single - relationship status is positively associated with
treatment counseling adherence.
H1DOA: Single - relationship status is positively associated with
abstinence from opioids.
H1DR: Single - relationship status is positively associated with
retention in treatment.
H2ACA: Higher education is positively associated with treatment
counseling adherence.
H2AOA: Higher education is positively associated with abstinence
from opioids.
H2AR: Higher education is positively associated with retention in
treatment.
H2BCA: Employment is positively associated with treatment
counseling adherence.
H2BOA: Employment is positively associated with abstinence from
opioids.
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Not
Supported
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X
X
X (ft)

X (pt)

Hypothesis
H2BR: Employment is positively associated with retention in
treatment.
H2CCA: Higher income is positively associated with treatment
counseling adherence.
H2COA: Higher income is positively associated with abstinence from
opioids.
H2CR: Higher income is positively associated with retention in
treatment.
H2DCA: Having health insurance is positively associated with
treatment counseling adherence.
H2DOA: Having health insurance is positively associated with
abstinence from opioids.
H2DR1: Having health insurance is positively associated with
retention in treatment.
H2DR2: Having public insurance is positively associated with
retention in treatment.
H3ACA: Readiness to change is positively associated with treatment
counseling adherence.
H3AOA: Readiness to change is positively associated with abstinence
from opioids.
H3AR: Readiness to change is positively associated with retention in
treatment.
H4ACA: Having social support is positively associated with treatment
counseling adherence.
H4AOA: Having social support is positively associated with
abstinence from opioids.
H4AR: Having social support is positively associated with retention
in treatment.
H5ACA: Receiving integrated care is positively associated with
treatment counseling adherence.
H5AOA: Receiving integrated care is positively associated with
opioid abstinence.
H5AR: Receiving integrated care is positively associated with
retention in treatment.
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Supported

Not
Supported

X (pt)

X (ft)
X
X
X

X
(public)
X
X
X
X
X
X
X
X
X
X
X
X

CHAPTER FIVE: DISCUSSION
Discussion of Findings
The aim of the study was to examine characteristics and factors associated with
counseling adherence, opioid abstinence, and retention in patients receiving MAT for up to one
year. The study focused on these three key areas because successful patient engagement in
treatment decreases drug use, and most importantly, mortality.
Personal Factors.
Personal Characteristics: The results of this study indicated that for personal
characteristics, gender, race and relationship status was not a significant factor associated with
counseling adherence, opioid abstinence or retention. These findings were supported in the
literature (Darker et al., 2016; Deck & Carlson, 2005; Banta-Green et al., 2009; Wasserman et
al., 2011). Age was the only personal characteristic which played a statistically significant role
when controlling for other factors in counseling adherence and retention in treatment. This was
consistent with research studies indicating an increase in age as a predictor of retention (Deck &
Carlson, 2005; Banta-Green et al., 2009; Wasserman et al., 2011; Darker et al., 2016; Joe et al.,
1998; Proctor et al, 2015). This is an important factor for clinicians to be mindful of. Especially
with the opioid epidemic shift to a younger population, treatment agencies may benefit from
utilizing evidence-based practices for adolescents and young adults to better engage and retain
the younger population in treatment.
Socio-economic Factors: Prior literature has shown a direct correlation between social
determinants of health, inclusive of socio-economic factors and health outcomes. Limited studies
however, have researched the influence of socio-economic factors influence on MAT outcomes
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(Darker et al., 2016; Rash, Andrade & Petry, 2013; Rash, Olmstead & Petry, 2009). This study
found there was no association with higher levels of education and counseling adherence, and
opioid abstinence. However, having lower education (patients with a high school diploma or
GED) was associated with retention. This is consistent with a study that found higher education
was not associated with retention in treatment (Darker et al., 2016). In terms of employment,
patients working part-time were more likely to be retained in treatment at one year. Those
working full-time were more likely to abstain from opioids. This is not surprising since many
jobs have Drug and Alcohol Policies which employees are required to adhere to as part of their
employment (Hartwell, Steele, French, & Rodman, 1996). O’Connell, Enev, Martin and Inciardi
(2007) also assert having employment instills a renewed sense of self- identity and benefits of

not using substances (p. 1093). A limitation of the study, which is discussed further below, is
this information was collected at intake. This also correlates with the income variable which had
all non-significant associations.
Health insurance had the most impactful association with the variables studied. In the
initial model, only public insurance (Medicaid, federal and state funding coverage) showed
statistical significance for adhering to counseling at one year. The associations were statistically
significant and had the lowest hazard ratios for the opioid abstinence and retention models.
Findings agree with Deck and Carlson (2005) and Banta-Green et al. (2009) who reported that
patients with public assistance funding were more likely to stay in treatment. This is a significant
factor as the epidemic has now received national attention. In the US President’s 2017 Public
Health Emergency declaration of the national crisis, allocating additional funding to treatment
was not included. Action for telemedicine, improving hiring process for addiction specialist,
dislocated worker grants and shift in HIV resources for those also affected by substance use were
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the focal areas of the declaration (The White House, United States Government, 2017). Although
this was an important step in the right direction, more is needed than just acknowledging the
epidemic, which has been an issue for quite some time. Funding to increase access to and
engagement in treatment was considerably missing from the declaration. Florida’s governor and
political leaders however, announced support for legislation towards public assistance funding
for the opioid crisis (Wilson, 2017). This is expected to pass during this year’s Florida legislative
session.
Readiness to change: This was not an influential factor in any treatment outcome, which
did not support the literature. A few studies indicated that treatment motivation was an important
factor in treatment success, with motivated patients more likely to abstain from opioids and stay
in treatment (Harrell et al., 2013; Kelly et al., 2011; Pantalon et al., 2002). Surprisingly, the
action phase (HR= 1.316) was statistically significant in the reverse direction, implying patients
were less likely to abstain from opioids at 365 days than those in the pre-contemplation phase.
This variable was assessed by the admissions counselor at intake; it would be interesting to see if
patients are in different phases during their treatment plan updates and if this had any effect on
the survival times.
Environmental Influences.
In examining the environmental factors both revealed significant associations.
Social Support: When controlling for other variables in the cox regression, only the
opioid abstinence models were significant, suggesting those with a support system were more
likely to abstain from opioids. This was consistent with two studies (Cavaiola et al. 2015;
Franckowiak & Glick, 2015) but was inconsistent with the Wasserman et al. (2001) article.
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These results suggest that addiction counselors can help patients abstain from opioids by
encouraging them to add positive support during treatment through group sessions or 12-step
programs.
Integrated care: All bivariate associations indicated positive associations with treatment
outcomes. In the cox regression, patients receiving integrated care were more likely to abstain
from opioids and retain in treatment (counseling adherence was not significant). As indicated in
the literature, integrated care improves patient-centered care and cost-effectiveness (Kelly et al.,
2011; Farber et al., 2012; HHS 2016). The Surgeon General’s 2016 report indicated both the
substance use and general health care workforces are undertrained to meet this need. “Health
care now requires a new, larger, more diverse workforce with the skills to prevent, identify, and
treat substance use disorders, providing “personalized care” through integrated care delivery”
(HHS, 2016, p.6-2). Additionally, health care and treatment agencies will need funding to not
only provide integrated treatment teams, but integrated services to meet patients’ needs.
Controls.
An analysis of the control variables revealed patients whose primary drug dependence
was heroin, were less likely to adhere to counseling, abstain from opioids, and retain in treatment
at one year than patients with a primary dependence of prescription drugs. The association to
opioid abstinence was consistent with the findings of Moore et al. (2007) but conflicted with
Banta-Green et al. (2009) in regard to retention. This population may require additional attention.
Counseling staff and treatment teams should utilize evidence-based curriculum, and work on
developing initiatives to further engage this population. Bivariate analysis revealed significant
associations with the medications used. Those on methadone were more likely to adhere to
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counseling sessions, whereas patients taking buprenorphine were more likely to abstain from
opioids and still be in treatment at one year. This may also directly correlate to available funding
(buprenorphine is costlier) and health coverage.
The study’s results were slightly different from the conceptual model in some respects.
With the guidance of the conceptual model, personal factors such as age, and insurance, in
addition to the environmental factors of social support and integrated care, were predictors to
counseling adherence, opioid abstinence, and retention in MAT. Though the concepts in the
models were interwoven, some personal factors -demographics, socio-economic and readiness to
change- showed no statistical significance to the treatment outcomes. The findings from the selfefficacy and readiness to change constructs were inconsistent with the literature. Nevertheless,
the conceptual model did appear to address the dynamic relation between personal factors or
environmental influences and behavior in certain instances. The outcome expectancies domain
from the social cognitive theory, in addition to the behavioral and normative constructs from the
theory of reasoned action.
Limitations
Several study limitations should be noted. The original use of the data were not for
research purposes. Therefore, variables such as support systems did not have additional
information to further identify the type of support, for example, whether it was a spouse, relative,
or friend. Additionally, the severity of patient’s addiction was not controlled for.
Though usage of data from clinical records has strengths, it also has limitations. Missing
data are a major limitation of using existing clinical records (Jacobsen, 2017). The assumption
cannot be made that the health record includes a full picture of each patient’s characteristics and
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treatment episode (Jacobsen, 2017, p. 164). Whether the missing data were patients lost to follow-up,
patients transferring, or staff’s inability to completely enter information into the clinical record;
statistical methods were employed to control for this. Survival analysis not only focuses on the time
variable, it censors data, whether missing, lost to follow-up, death or patients not accounted for
during the treatment timeframe.

Also, the measures may not have been completely reliable or valid. Many of the
independent variables were collected upon admission and could have changed over the year in
which the study measured the survival of the patient. Future studies should include a feasible
follow-up period to evaluate any changes in patient’s status, for instance the education level,
income, support systems, since stabilizing in treatment. Additionally, the initial intake
assessment relies on self-report for some questions. Patients’ recall of factors such as criminal
history, education level, income, and support system may be biased.
Finally, in observational studies, unlike experimental studies, findings may suggest, but
do not determine, a causal pathway. Variables that affected the findings that are not included in
the analysis may have biased the results (omitted variable bias) (Carlson & Morrison, 2009).
Strengths & Generalizability
The generalizability of the research study should be carefully considered as the data were
from a single city in Florida. The most recent demographics for Florida from SAMSHA’s
Treatment Episode Data Sets (TEDS) for opioid dependent admissions is 2013. Florida is one of
over 20 states which more recent information is not available. Although comparable for age and
race, gender shows almost the reverse of the percentages usually encountered, with the majority
of opioid dependents being male in the TEDS data. However, in general this statistic is shifting
nationally (Banta-Green et al., 2009). Additionally, the patients in the sample received treatment
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at a not-for-profit MAT facility, and as the sample characteristics illustrated, included mostly
low-income persons, of which a good portion received public assistance. Therefore, these
findings may not be generalizable to the entire population.
Despite the limitations listed above, retrospective cohort designs using clinical records
also have strengths. Neither the patient nor services provided by the treatment agency was
influenced by being included in the study. Furthermore, use of data from clinical records
eliminates the need for additional required resources, essentially time and money, in the
collection of primary data (Song, & Chung, 2010). Clinical records from a large behavioral
agency provided the advantage of a large sample size and detailed data that would not have
otherwise been feasible.
The study extends the literature, as few studies have examined retention with a large
sample size in MATs using cox regression analysis (Hser et al., 2013). This study goes beyond
prior research in also studying counseling adherence and opioid abstinence as outcome variables,
instead of solely focusing on retention. Since methadone was the only accepted treatment for
opioid abstinence for a long time, few studies have also included buprenorphine patients.
Additionally, the sample included a large percentage of those whose primary drug dependence
was non-medicinal prescription drugs.
Lastly, the study addresses a very timely issue, as the opioid epidemic was responsible
for more than 42,000 deaths in the US in 2016 (CDC, 2017). Understanding factors influencing
treatment outcomes assists the substance use disorder workforce when assessing and engaging
patients in treatment. Equally important, it provides policy and lawmakers with data showing the
need for funding and initiatives targeting community providers to collaborate in integrated care
services.
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Implications
Given the current opioid epidemic in the United States, particularly in the state of Florida
where the study sample is from, this study has significant implications for policies, such as
legislative initiatives, and programs, such as effective treatment modalities and MAT expansions.
The following sections discuss some of these policy and programmatic implications.
Policy Implications.
In 2016, Florida had over 5,725 opioid-related deaths (a 35% increase from the prior
year), yet the state does not have an office tracking the epidemic (Duran, 2018). Governor Scott
in 2009 eliminated The Office of Drug Control (Duran, 2018). Such an agency needs to be at the
forefront of the epidemic, to utilize collaborative teams to assess, treat, and prevent the crisis.
Studies such as this would provide viable information to a centralized office working on the
epidemic in the State.
The 2018 Florida Legislative session introduced House Bill 1025 to reinstate the Office
of Drug Control. The bill lists a number of responsibilities of the agency inclusive of monitoring
state policies and data (including overdoses) related to substance use, developing a strategic plan
to reduce substance use within the State, working with the behavioral health managing entities
throughout the state for resources and advocacy, conducting media campaigns on the negative
effects of substance use and making policy recommendations (Florida House of Representatives,
2018). However, the bill was indefinitely postponed and withdrawn from consideration. Having
a central agency to establish an assessment of the State’s needs and create a comprehensive plan
to overcome the epidemic should be reconsidered for the next session. An additional
recommendation in the policy would be to assess the opioid addiction treatment workforce in the
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State and the collaborative efforts of treatments agencies providing integrated care. The study
highlighted patients receiving integrated care were more likely to abstain from opioids and retain
in treatment. The US Surgeon General in the Facing Addiction in America Report highlighted
the importance of integrated care systems in healthcare (HHS, 2016). Furthermore, calling to
attention the need to workforce needs – “Well-supported evidence shows that the current
substance use disorder workforce does not have the capacity to meet the existing need for
integrated health care, and the current general health care workforce is undertrained to deal with
substance use related problems” (HHS, 2016, p. 6-2).
The availability of funding/coverage to pay for treatment services was a key factor for
patients’ survival time in MAT. The study indicated in each of the cox regression models that the
availability of health insurance coverage to pay for treatment was significant. Self-pay patients
without private insurance or public funding were less likely adhere to counseling, abstain from
opioids and retain in treatment. This is of importance, as the US President in October 2017
declared a Nationwide “Public Health Emergency” to address the opioid epidemic but fell short
of requesting funds for treatment. Florida’s Governor recently announced proposing $50 million
($27 million from federal funds) in the budget towards combating the opioid epidemic, which
will be important during this legislative session (Office of Governor Rick Scott, 2017). Adequate
funding is necessary for successful treatment outcomes. State legislators initially planned to
request an additional $25 million for treatment, however the recent events in Florida, became
more of a priority for resources towards gun control (Mower, 2018). Florida’s recent budget
proposal (HB 5001: General Appropriations Act) includes $704 million to community substance
and mental health services ($19 million decrease from the prior year) (Florida Senate, 2018). The
appropriations act often includes non-reoccurring funds, with the exception of a few member
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projects, special projects or populations, for instance women special funding (pregnant, postpartum and their affected families), family intensive treatment, funding for specific treatment
agencies and Sheriff Office’s (Florida Department of Children and Families, 2018). With the
current opioid epidemic in the state, and the study illustrating the funding need for a higher
probability a recommendation of reoccurring funds specifically for Medication Assisted
treatment programs would be ideal.
House Bill 1025 also includes a request for a Medicaid waiver. Florida is one of nineteen
states, which did not expand Medicaid under the Affordable Care Act (ACA), which leaves just
under half a million people in the coverage gap (Norris, 2017). The Agency for Health Care
Administration can request federal approval for treatment (inclusive of MAT) to support services
that Medicaid does not cover without the waiver to improve access and quality of services
thereby assisting to restore the care continuum (Florida House of Representatives, 2018, p. 4)
In terms of federal policy, repealing the Affordable Care Legislation will have
detrimental effects to this population (Bailey, 2017; Zezima & Ingraham, 2017). The study
illustrated the importance of public funding, of which a larger majority of the patients was on
Medicaid. It is estimated that under an ACA repeal, over 2.8 million people with a substance use
disorder (220,000 with an opioid disorder) could lose health care coverage (Bailey, 2017, para.
3). Throughout the nation, and in the State of Florida, the need remains high for opioid addiction
treatment. A reduction in coverage will create an adverse effect in combating the epidemic.
Program Implications.
Age was the only personal factor statistically significant when controlling for other
factors in counseling adherence, and treatment retention. Proctor et al. (2015) asserts younger
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patients’ maturity levels and understanding of negative consequences of substance use may cause
less success in treatment outcomes. Efforts to increase engagement of younger adults in
treatment adherence, by utilizing evidence-based models focused on young adults or adolescents,
to retain them in treatment is warranted. Focusing on early intervention treatment techniques integrating motivational enhancement, and therapeutic groups based on age- could also be
beneficial for the younger patients (Proctor et al., 2015).
Treatment providers should also highly encourage family/support groups or require 12Step Programs (Methadone Anonymous) to increase social support. The study indicated those
with a support system were more likely to abstain from opioids. Cavaiola et al. (2015) findings
indicated patients were appreciative of a number of different factors from the support systems.
Therapeutic support groups could be beneficial in helping the family/support system understand
how to express belief/confidence in their recovery, being honest, refraining from being critical
and expressing concern (Cavaiola et al., 2015, p. 190).
Providing patient-centered care, inclusive of integrated care services, is also a
collaborative effort that requires resources for training, services, and staff. Also, from a clinical
standpoint, resources should also be allocated to the treatment of heroin (not just opioids in
general). Patients with a heroin primary drug dependence were less likely to adhere to
counseling, abstain from opioids, and retain in treatment than those with a primary drug
dependence of prescription drugs.
From the context of health and public affairs, it is essential that policymakers, health care
professionals and researchers work collectively to ensure that public funding is allocated to MAT
programs, to ensure continuation in treatment. Efforts to increase funding for opioid abuse
treatment and additional research for evidence-based interventions for heroin and non-medicinal
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prescription drug interventions are needed. Also utilizing an interdisciplinary approach to
support integrative care services being provided throughout MATs. The overall benefits of
treatment and factors that increase survival for more than a year will enable citizens to be
positive and productive.
Future Research
While this was an important study on the association of personal and environmental
factors and treatment outcomes, additional research is needed to address the current opioid
climate. First, unfortunately patients on vivitrol did not have their clinical information in the
EHR and could therefore not be included in the study. Having a study inclusive of patients on
vivitrol is important, as there is not much literature on this medication in regard to survival
analysis in MAT. Comparative effectiveness studies need to be conducted to see if there are
differences between patients on this medication in comparison to others. Unlike with methadone
and buprenorphine, patients are required to have that initial detoxification period prior (seven to
ten days minimum) and can take the medication via injection or orally once per month (instead
of daily).
As this study suggests, personal factors do not play a large role in treatment outcomes
whereas the treatment environment and social support do; it is also important to study the context
of the treatment environment and patients’ social context. For example, quantitative studies
should be conducted that: examine close relationships that may increase the risk of opioid use;
define the settings in which social relationships occur; and explore the social and cultural norms
in relation to opioid abuse and treatment. Qualitative studies could explore the contextual and
environmental issues in detail. Such qualitative and quantitative studies could address the
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personal factors and environmental influences linkage that was not studied in the triangular
conceptual model utilized in this study (see Figure 8).
Additionally, subsequent research should assess the needs of substance use agencies to
provide integrated care. This is imperative to improve care coordination, and financial costs to
both the patients and providers, and an area, which the US Surgeon General said both the health
and substance use workforce are lacking the capacity to meet the needs of an integrative care
system (HHS, 2016; Stone & Katz, 1996). In addition, research is needed to examine the
knowledge and beliefs of patient-centered integrated care with the addiction and health
workforces to be able to develop necessary trainings to engage more patients in integrated care.
Finally, it will be intriguing to understand how the cost of medications and treatment
coverage compare across private insurance providers. Whether insurance companies limit the
length of time patients are able to receive services, or medications received -methadone,
buprenorphine, or vivitrol. Furthermore, with the increase in primary-care providers treating this
population, it will also be beneficial to examine treatment outcomes in the primary care
outpatient office setting in comparison to MATs.
Conclusion
The objective of this study was to determine if treatment outcomes, measured by
counseling adherence, opioid abstinence, and retention, were influenced by personal
characteristics, socio-economic factors, readiness to change, social support and integrated care.
Guided by a conceptual framework inclusive of social cognitive theory, transtheoretical model,
and theory of reasoned action; a retrospective cohort design was conducted. Bivariate analyses
and three cox regression models revealed factors associated with positive treatment outcomes.
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This dissertation expands the literature and contributes to the knowledge of
characteristics and factors associated with MAT outcomes. MAT is a pivotal step in preventing
relapse and reducing opioid mortality. The study provides crucial information on the need for
funding to support patients’ continual efforts to engage in treatment. As the opioid epidemic has
become a national public health concern, having treatment interventions inclusive of support
systems and integrated care in addition to the availability of funding for treatment is of uttermost
importance to achieve care continuum.
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Table 14. Prior Medication Assisted Treatment Studies
Author & Pub. Year
Title
Banta-Green et al.,
Retention in methadone
2009
maintenance drug
treatment for prescriptiontype opioid primary users
compared to heroin users

Saxon et al., 2013

Medication-assisted
treatment for opioid
addiction:
Methadone and
buprenorphine

Type of Study
Design: Retrospective
cohort study

Critical Findings
Not adjusting for other
factors, odds of retention
for PDU was 1.33 (95%
Analysis: Logistic
CI, 1.03, 1.71).
Regression
Odds of retention for
PDU in comparison to
Sample: heroin and
heroin users: 1.25 (95%
prescription drug users
CI, 0.93, 1.67). No
receiving MMT in WA.
statistical difference in
(n = 2308
treatment type when
adjusting for tx
agencies, public
assistance type, services
– medical, psychiatric,
legal, familial, and
demographics
Design: Randomized
Summarizes clinical
Better tx retention for
Control Trial
use and pharmacology
methadone.
of
Decrease illicit opioid
Sample:
Methadone and
use early in tx with
Opioid dependents
Buprenorphine
buprenorphine.
(n = 1269)
treatment for opioid use Risk behavior (injection
disorder
drug use) decline14.4 to
2.4% for buprenorphine
and 14.1 to 4.8% for
methadone (p < .001).
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Focus
Assess retention in
treatment for opioid
dependent prescription
drug users in
comparison to heroin
users

Author & Pub. Year
Kresina & Lubran,
2011

Title
Improving Public Health
Through Access to and
Utilization of Medication
Assisted Treatment

Type of Study
Theoretical

Darker at al., 2016

Demographic and clinical
factors predicting
retention in methadone
maintenance: results from
an Irish cohort

Design: Cross sectional
Analysis: Binary
Logistic regression
Sample: patients
receiving MMT in
Ireland
(n= 189)
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Focus
Providing integrated
care and improving
care coordination for
access to and utilization
of Medication Assisted
Treatment
To explore the
demographic and
clinical factors
predicting retention in
Methadone
Maintenance
Treatment.

Critical Findings
Integrated Models of
MAT
Coordination Care
Models for MAT

Characteristics of
patients who had fewer
breaks in tx: single,
older, living in their own
home, medication –
higher methadone dose
or taking antipsychotic
meds
Factors enabling regular
attendance at MMT:
Sobriety (37.5 %), to
avoid withdrawals
(16.1 %), methadone
dependence (13.9 %)
and additional services
(10.2 %,).

Author & Pub. Year
Moore et al., 2007

Title
Primary Care Officebased Buprenorphine
Treatment: Comparison
of Heroin and Prescription
Opioid Dependent
Patients

Type of Study
Design: Randomized
clinical trial
Analysis:
Multinomial Logistic
Regression

Focus
To compare
characteristics and tx
outcomes of heroin and
prescription use opioid
dependents.

Sample: adults
receiving primary care
buprenorphine tx
(n=200)

Timko et al., 2016

Retention in medicationassisted treatment for
opiate dependence: A
systematic review.

Design: Randomized
control trials
Analysis: Systematic
Review
Sample: 55 articles
between 2010 - 2014
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Reviewing literature on
retention in medication
assisted treatment.

Critical Findings
Prescription opioid
dependents are
associated with
improved treatment
outcomes over heroin
dependents.
POD characteristics:
younger, less opioid use,
more likely to be white,
with higher earning
incomes
POD vs heroin patients:
completing treatment:
59% vs. 30%.
Length of stay: 21.0 vs.
14.2 weeks
Rate of negative US
56.3% vs. 39.8%,
all p values < .05.
Retention rates varied
from 3 months to over a
year.
Retention rates were
highest in
buprenorphine/naloxone.
1 study measured
retention in treatment
over a year.
Studies with larger
samples and longer-term
follow-ups are needed.

Author & Pub. Year
Franckowiak & Glick,
2015

Title
The effect of self-efficacy
on treatment

Type of Study
Design:
Experimental – PrePost Test
Analysis: t-test and
correlation

Focus
Measuring the
association between
self-efficacy and tx
outcomes for opioid
dependent MAT
patients

Sample: Convenience
sample, 50 opioid
dependent MAT
patients

Zhang et al., 2003

Does retention matter?
Treatment duration and
improvement in drug use

Design:
Longitudinal cohort
Analysis:
Linear regression

There was no correlation
between negative drug
screens and self –
efficacy.

To examine a
relationship (minimum
threshold, continuous
or non-linear) between
treatment duration and
drug use improvement

Sample: 62 drug
treatment units, 4005
patients

Author & Pub. Year

Title

Type of Study
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Critical Findings
Average increase in
general GSE scores: 5.1
points, when comparing
pre and post-test at a
95% CI. Total scores
increased an average of
10.1 points. P< .01

There was no correlation
with number of
counseling sessions and
self –efficacy.
Positive linear
relationship with
duration in treatment,
and drug use
improvement for MMT
Retention in outpatient
(non-MMT and longterm residential was less
predictive)

Focus

Critical Findings

Hubbard et al., 2003

Kelly et al., 2011

Overview of 5-year
follow-up outcomes in the
drug abuse treatment
outcome studies
(DATOS)

Predictors of methadone
treatment retention from a
multi-site study: A
survival analysis

Design:
Longitudinal
Analysis: paired t-test,
logistic regression
Sample: 1,393 patients
from 96 treatment
programs
Design:
Longitudinal
Analysis:
Cox proportional
hazards regression
Sample: Convenience
sample, 361 MMT
patients

To describe and
examine the association
between treatment
duration and modalities
– outpatient methadone,
outpatient, short term
inpatient, and long term
residential
Examining predictors
of three domains –
personal, program and
community factors –
for opioid dependent
MMY patients.

Duration of 6 months or
greater in treatment was
associated with
decreased criminal
activity and full-time
employment increase

3-month retention
predictors: being female,
higher treatment
readiness at admission
(p = .005); but lower
desire for help, (p =
.010).
1-year retention: higher
medical and lower legal
composite scores; in
addition to higher
treatment satisfaction at
3-months
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APPENDIX B: THEORETICAL APPROACHES LITERATURE
REVIEW SUMMARY
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Table 15. Theoretical Approaches Literature Review Summary
Author &
Title
Theory
Type of Study/
Pub. Year
Unit of Analysis
Gullo et al.,
Social cognitive
Social
Cross-Sectional
2017
predictors of treatment Cognitive
UOA: substance
outcome in cannabis
use – cannabis
dependence
patients

Focus

Critical Findings

Treatment
outcomes in
cannabis
dependence,
testing
expectancies and
refusal selfefficacy as
predictors

Abstinence increased with tx
sessions (1.20x more likely).
Negative expectancies
increased the odds of
abstinence, as was emotional
relief refusal.
Emotional relief refusal selfefficacy predictor of improved
treatment outcomes; and was
also a mediator of positive
expectancy outcomes
Self-efficacy beliefs create
desired changes
Guides:
Assessment of self-efficacy
Enabling community (for
negative drug use)
Social vs individual models
Predictors: low controlled use
of self-efficacy was a predictor
of abstinence acceptance.
Increasing levels of abstinence
acceptance was associated with
drug abstinence.
An increase in abstinence
acceptance was associated with
a decreased controlled selfefficacy.

Bandura,
1999

A socio-cognitive
analysis of substance
abuse: an agentic
perspective

Social
Cognitive

Theoretical

Analysis of SU

Fiorentine &
Hillhouse,
2001

When low selfSocial
efficacy is efficacious: Cognitive
toward an addictedself model of cessation
of alcohol- and drug
dependent behavior

Prospective
cohort

Examine the
relationship
between selfefficacy and
behaviors –
alcohol cessation
and drugdependent
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Author &
Pub. Year
Dijkstra et
al., 2006

Title

Theory

Is social cognitive
theory becoming a
transtheoretical
model?

Social
Cognitive

Sharma,
2005

Enhancing the
Social
effectiveness of
Cognitive
alcohol and drug
education programs
through social
cognitive theory
Motivation to change
Transtheoretical
and readiness for
counseling in
prescription-drugdependent patients in a
general hospital
setting

Schmidt et
al., 2009

Harrell et al.,
2013

A latent class
approach to treatment
readiness corresponds
to a transtheoretical
("stages of change")
model

Type of Study/
Unit of Analysis

Theoretical

Design: Crosssectional
Analysis: U test
and chi-square
Sample: 45
prescription drug
dependents
(952 hospital
patients)
Transtheoretical Design: Crosssectional,
Interview
Analysis: latent
class
Sample: 539
cocaine and
opioid users
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Focus

Critical Findings

Application of
theory to Alcohol
and Drug
Education
Programs

At the 2-month follow-up, the
matched interventions were
significantly more effective in
stimulating forward stage
transition
Various substance abuse
studies presented on the theory
1983 – 2004.
Highlights Bandura’s 3-level
implementation model.

To investigate the
motivation to
change and
willingness to
accept
consultations in
prescription drug
dependent
patients
Analyze
readiness for
treatment

Majority of the population was
in pre-contemplation stage,
followed by contemplation
stage.
Self-efficacy to change was
associated with readiness to
change.
Receiving counseling was also
rated positive
Pre-contemplative phase
significantly more likely to test
for marijuana, whereas the
action phase was significantly
less likely to test positive for
opioids.

Author &
Pub. Year
Pantalon et
al., 2002

Title
The URICA as a
measure of motivation
to change among
treatment-seeking
individuals with
concurrent alcohol and
cocaine problems.

Prochaska & The transtheoretical
Velicer, 1997 model of health
behavior

Theory

Type of Study/
Unit of Analysis
Transtheoretical Design: Crosssectional
Analysis:
confirmatory
factor analysis
Sample: 106 in a
pharmacotherapy
randomized
control trial
Transtheoretical Theoretical
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Focus

Critical Findings

Evaluating the
URICA as a
motivation to
change
assessment

Committed action: significantly
higher percentage of abstinent
days in comparison to lower
phases (85.6% vs 72.7%, p <
.01)

Providing an
understanding of
the constructs
and stages of
change

Identifying the core constructs:
stages of change, processes of
change, decisional balance,
self-efficacy, temptation
Assumptions: complexities of
behavioral change require more
than a single theory, behavior
change is a process, planned
intervention is required for
behaviors change in the
population, at-risk populations
are usually not prepared for
action, specific
interventions/process need to
occur at identified stages for
progress to occur, and chronic
behavior patterns are usually a
result of biological, social and
self-control

Author &
Pub. Year
Roberto et
al., 2014

Kleinman et
al., 2002)

Title

Theory

Predicting substanceabuse treatment
providers'
communication with
clients about
medication assisted
treatment: A test of the
theories of reasoned
action and planned
behavior
Predicting long-term
treatment utilization
among addicts
entering
detoxification: the
contribution of helpseeking models

Theory of
Reasoned
Action

Type of Study/
Unit of Analysis
Retrospective
cohort

Focus

Critical Findings

Examine if TRA
& TPNB can
predict tx
providers
encouraging
patients to use
MAT

Confirms TRA application as a
conceptual model for
explaining attitudes and
intentions (counselor’s) and
linkage of social norms. SEM
showed significant relation b/w
intentions & behavior, attitudes
& intentions, and norms and
intentions.

Cross-sectional

Examining sociodemographics as
predictors of
long-term
treatment

TRA/TPB was the most
effective in predicting use of
treatment programs.
Hierarchical MR: Being
homeless was the only sociodemographic variable found to
significantly predict tx at the
1st stage. On the 2nd stage:
being on parole and using
drugs regularly for fewer than
20 years were also predictors
with homelessness.
Treatment utilization is
predicted by behavioral beliefs
favoring treatment and selfefficacy at the third stage.

Theory of
Planned
Behavior

Combination of
theories
including:
Theory of
Reasoned
Action
Theory of
Planned
Behavior
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UOA: opioid
dependents

Author &
Pub. Year
Madden,
Ellen &
Ajzen, 1992

Title

Theory

A comparison of the
Theory of Planned
Behavior and the
Theory of Reasoned
Action

Theory of
Reasoned
Action

Rich et al.,
2015

Theory of planned
behavior and
adherence in chronic
illness: a metaanalysis

Johnston,
White &
Norman,
2004

An examination of the
Individual-Difference
Approach to the Role
of Norms in the
Theory of Reasoned
Action

Theory of
Reasoned
Action
Theory of
Planned
Behavior
Theory of
Reasoned
Action

Type of Study/
Unit of Analysis
Quasiexperimental
Pretest

Focus

Comparison of
both theories by
measuring
attitudes toward
UOA:
performing
undergraduate
behaviors
business students identified by the
subjects
Meta-analysis
Theory as a
predictor of
treatment
adherence

Theory of
Planned
Behavior

longitudinal
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Examining
individualdifference
approach in
subjective norms
weak predictor of
behavioral
intentions in
undergraduate
students

Critical Findings
Inclusion of behavioral control
is an indicator of practice and
intention.
Effects of perceived behavior
control are most telling when
the behavior presents a problem
with control.
Explained 33% of variance in
intention and 9% in adherence
behavior.
Results support theory
predictions, though effect sizes
were small.
Both individuals and behaviors
are associated with normative
and attitudinal control.
Combined for 85%health
intention variance.
Closer examination of social
influences to address the weak
association between subjective
norm and intention.

Author &
Pub. Year
Millstein,
1996

Title

Theory

Utility of the theories
of reasoned action and
planned behavior for
predicting physician
behavior: A
prospective analysis

Theory of
Reasoned
Action

Type of Study/
Unit of Analysis
Cross-sectional
Survey

Focus

Predicting
physicians’
delivery of
UOA: physicians preventive
services for
educating
adolescent
patients about the
transmission of
HIV and other
sexually
transmitted
diseases.
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Critical Findings
Studies in the past have found
attitudes to have the stronger
association (not social norms)
on behavioral intentions.
Behavioral intentions were
strongly associated with
attitudes and social norms
(strongest influence) towards
the behavior – prescribing
antibiotics.
Perceived behavioral control
had direct effects on behavior
and interacting with social
norms and behavioral
intentions.
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